<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE Publisher PUBLIC "-//Springer-Verlag//DTD A++ V2.4//EN" "http://devel.springer.de/A++/V2.4/DTD/A++V2.4.dtd">
<Publisher>
  <PublisherInfo>
    <PublisherName>Springer New York</PublisherName>
    <PublisherLocation>New York, NY</PublisherLocation>
    <PublisherImprintName>Springer</PublisherImprintName>
  </PublisherInfo>
  <Book Language="En">
    <BookInfo BookProductType="Contributed volume" ContainsESM="No" Language="En" MediaType="eBook" NumberingStyle="ChapterOnly" OutputMedium="All" TocLevels="0">
      <BookID>978-1-60327-829-4</BookID>
      <BookTitle>Drug Management of Prostate Cancer</BookTitle>
      <BookDOI>10.1007/978-1-60327-829-4</BookDOI>
      <BookTitleID>158057</BookTitleID>
      <BookPrintISBN>978-1-60327-831-7</BookPrintISBN>
      <BookElectronicISBN>978-1-60327-829-4</BookElectronicISBN>
      <BookChapterCount>37</BookChapterCount>
      <BookCopyright>
        <CopyrightHolderName>Springer Science+Business Media, LLC</CopyrightHolderName>
        <CopyrightYear>2010</CopyrightYear>
      </BookCopyright>
      <BookSubjectGroup>
        <BookSubject Code="SCH" Type="Primary">Medicine &amp; Public Health</BookSubject>
        <BookSubject Code="SCH33160" Priority="1" Type="Secondary">Oncology</BookSubject>
        <BookSubject Code="SCH62002" Priority="2" Type="Secondary">Urology</BookSubject>
        <BookSubject Code="SCH33002" Priority="3" Type="Secondary">Internal Medicine</BookSubject>
        <SubjectCollection Code="SUCO11650">Medicine</SubjectCollection>
      </BookSubjectGroup>
    </BookInfo>
    <BookHeader>
      <EditorGroup>
        <Editor AffiliationIDS="AffID1">
          <EditorName DisplayOrder="Western">
            <GivenName>William D.</GivenName>
            <FamilyName>Figg</FamilyName>
          </EditorName>
          <Contact>
            <Phone>301402-3622</Phone>
            <Fax>301402-8606</Fax>
            <Email>wdfigg@helix.nih.gov</Email>
          </Contact>
        </Editor>
        <Editor AffiliationIDS="AffID2">
          <EditorName DisplayOrder="Western">
            <GivenName>Cindy H.</GivenName>
            <FamilyName>Chau</FamilyName>
          </EditorName>
          <Contact>
            <Email>chauc@mail.nih.gov</Email>
          </Contact>
        </Editor>
        <Editor AffiliationIDS="AffID3">
          <EditorName DisplayOrder="Western">
            <GivenName>Eric J.</GivenName>
            <FamilyName>Small</FamilyName>
          </EditorName>
          <Contact>
            <Phone>415/353-7171</Phone>
            <Email>smalle@medicine.ucsf.edu</Email>
          </Contact>
        </Editor>
        <Affiliation ID="AffID1">
          <OrgDivision>Medical Oncology Branch</OrgDivision>
          <OrgName>NIH National Cancer Institute</OrgName>
          <OrgAddress>
            <Street>Rockville Pike 9000</Street>
            <City>Bethesda</City>
            <Postcode>20892</Postcode>
            <State>Maryland</State>
            <Country>USA</Country>
          </OrgAddress>
        </Affiliation>
        <Affiliation ID="AffID2">
          <OrgDivision>Medical Oncology Branch</OrgDivision>
          <OrgName>NIH National Cancer Institute</OrgName>
          <OrgAddress>
            <Street>Rockville Pike 9000</Street>
            <City>Bethesda</City>
            <Postcode>20892</Postcode>
            <State>Maryland</State>
            <Country>USA</Country>
          </OrgAddress>
        </Affiliation>
        <Affiliation ID="AffID3">
          <OrgDivision>School of Medicine, Dept. Urology</OrgDivision>
          <OrgName>University of California, San Francisco</OrgName>
          <OrgAddress>
            <Street>Divisadero Street 1600</Street>
            <City>San Francisco</City>
            <Postcode>94115</Postcode>
            <State>California</State>
            <Country>USA</Country>
          </OrgAddress>
        </Affiliation>
      </EditorGroup>
    </BookHeader>
    <Part ID="Part3">
      <PartInfo OutputMedium="All" TocLevels="0">
        <PartID>3</PartID>
        <PartNumber>Part II</PartNumber>
        <PartSequenceNumber>3</PartSequenceNumber>
        <PartTitle>Chemotherapy</PartTitle>
        <PartChapterCount>6</PartChapterCount>
        <PartContext>
          <BookID>978-1-60327-829-4</BookID>
          <BookTitle>Drug Management of Prostate Cancer</BookTitle>
        </PartContext>
      </PartInfo>
      <Chapter ID="Chap16" Language="En">
        <ChapterInfo ChapterType="OriginalPaper" ContainsESM="No" Language="En" NumberingStyle="ChapterOnly" OutputMedium="All" TocLevels="0">
          <ChapterID>16</ChapterID>
          <ChapterNumber>Chapter 16</ChapterNumber>
          <ChapterDOI>10.1007/978-1-60327-829-4_16</ChapterDOI>
          <ChapterSequenceNumber>16</ChapterSequenceNumber>
          <ChapterTitle Language="En">Microtubule Targeting Agents</ChapterTitle>
          <ChapterFirstPage>179</ChapterFirstPage>
          <ChapterLastPage>194</ChapterLastPage>
          <ChapterCopyright>
            <CopyrightHolderName>Springer Science+Business Media, LLC</CopyrightHolderName>
            <CopyrightYear>2010</CopyrightYear>
          </ChapterCopyright>
          <ChapterHistory>
            <RegistrationDate>
              <Year>2010</Year>
              <Month>4</Month>
              <Day>16</Day>
            </RegistrationDate>
            <OnlineDate>
              <Year>2010</Year>
              <Month>8</Month>
              <Day>3</Day>
            </OnlineDate>
          </ChapterHistory>
          <ChapterGrants Type="Regular">
            <MetadataGrant Grant="OpenAccess"/>
            <AbstractGrant Grant="OpenAccess"/>
            <BodyPDFGrant Grant="Restricted"/>
            <BodyHTMLGrant Grant="Restricted"/>
            <BibliographyGrant Grant="Restricted"/>
            <ESMGrant Grant="Restricted"/>
          </ChapterGrants>
          <ChapterContext>
            <PartID>3</PartID>
            <BookID>978-1-60327-829-4</BookID>
            <BookTitle>Drug Management of Prostate Cancer</BookTitle>
          </ChapterContext>
        </ChapterInfo>
        <ChapterHeader>
          <AuthorGroup>
            <Author AffiliationIDS="Aff1_16" CorrespondingAffiliationID="Aff1_16">
              <AuthorName DisplayOrder="Western">
                <GivenName>Antonio</GivenName>
                <GivenName>Tito</GivenName>
                <FamilyName>Fojo</FamilyName>
              </AuthorName>
              <Contact>
                <Email>fojot@mail.nih.gov</Email>
              </Contact>
            </Author>
            <Author>
              <AuthorName DisplayOrder="Western">
                <GivenName>David</GivenName>
                <GivenName>E.</GivenName>
                <FamilyName>Adelberg</FamilyName>
              </AuthorName>
            </Author>
            <Affiliation ID="Aff1_16">
              <OrgDivision>Experimental Therapeutics Section, Medical Oncology Branch, Center for Cancer Research</OrgDivision>
              <OrgName>National Cancer Institute</OrgName>
              <OrgAddress>
                <City>Bethesda</City>
                <State>MD</State>
                <Country>USA</Country>
              </OrgAddress>
            </Affiliation>
          </AuthorGroup>
          <Abstract ID="Abs1_16" Language="En" OutputMedium="All">
            <Heading>Abstract</Heading>
            <Para TextBreak="No">Microtubules are intracellular filamentous structures that comprise the cytoskeleton of all eukaryotic cells. They play a critical role in various cellular processes such as mitosis and have become an essential target for the chemotherapeutic approach to a wide spectrum of malignancies. It is thus crucial to understand the basic biology of the microtubule and be familiar with the various microtubule targeting agents used clinically. This chapter provides an overview of microtubule physiology and the novel microtubule-targeting chemotherapeutic agents that are currently being evaluated for the treatment of taxane-refractory, castration-resistant prostate cancer.</Para>
          </Abstract>
          <KeywordGroup Language="En" OutputMedium="All">
            <Heading>Keywords</Heading>
            <Keyword>Cytoskeleton</Keyword>
            <Keyword>Microtubule</Keyword>
            <Keyword>Tubulin</Keyword>
            <Keyword>Chemotherapy</Keyword>
            <Keyword>Prostate cancer</Keyword>
          </KeywordGroup>
        </ChapterHeader>
        <Body>
          <Section1 ID="Sec1" Type="Introduction">
            <Heading>Introduction</Heading>
            <Para TextBreak="No">Because of its crucial roles in cellular physiology, it is not surprising that the microtubule cytoskeleton has emerged as one of the most effective targets for cancer therapeutics. Interest in this validated target has led to the identification of an increasing number of structurally diverse compounds that interact with soluble tubulin and the microtubule cytoskeleton. Compounds that interact with tubulin and/or the microtubules can be divided into two major classes: By preferentially binding to the alpha/beta-tubulin heterodimer, agents comprising the first class (depolymerizing or destabilizing agents) inhibit microtubule polymerization. In contrast, agents with a binding site on the microtubule polymer act principally by stabilizing microtubules (polymerizing or stabilizing agents). Depolymerizing agents include vinblastine (Velbe<Superscript>®</Superscript>), vincristine (Oncovin<Superscript>®</Superscript>), vinorelbine (Navelbine<Superscript>®</Superscript>), vindesine (Eldisine<Superscript>®</Superscript>), vinflunine, cryptophycins, halichondrins, dolastatins, estramustine, 2-methoxyestradiol (2-ME), colchicine, and combretastatins [<CitationRef CitationID="CR1_16">1</CitationRef>–<CitationRef CitationID="CR3_16">3</CitationRef>]. Microtubule-stabilizing agents include paclitaxel (Taxol<Superscript>®</Superscript>, the first identified in this class), docetaxel (Taxotere<Superscript>®</Superscript>), the epothilones, including the recently approved epothilone B analog, ixabepilone (Ixempra<Superscript>®</Superscript>), and other mechanistically similar but structurally unrelated natural products such as discodermolide, the eleutherobins, sarcodictyins, laulimalide, rhazinilam, and certain steroids and polyisoprenyl benzophenones [<CitationRef CitationID="CR2_16">2</CitationRef>, <CitationRef CitationID="CR4_16">4</CitationRef>].</Para>
          </Section1>
          <Section1 ID="Sec2">
            <Heading>The Microtubule Cytoskeleton: Structure, Function, and the Importance of Microtubule Dynamics</Heading>
            <Para TextBreak="No">Agents targeting tubulin and the microtubule have emerged as active chemotherapeutic agents because of the essential function microtubules perform in eukaryotes. These diverse cellular functions include important roles in mitosis, meiosis, motility, maintenance of cell shape, and intracellular trafficking of macromolecules and organelles [<CitationRef CitationID="CR5_16">5</CitationRef>–<CitationRef CitationID="CR7_16">7</CitationRef>]. As the name implies, microtubules are hollow cylindrical tubes and these are formed by the self-association of alpha/beta-tubulin heterodimers into polymers. The tubulin heterodimers associate in a head-to-tail fashion to form linear filaments, referred to as protofilaments, and 12–13 of these in turn associate in a lateral manner to form hollow microtubules. On cross section, one sees the protofilaments assembled in a circle lining the outside of a hollow tubule. The arrangement of the protofilaments imparts polarity to the structure. The alpha subunits of the tubulin dimer are exposed at the “minus end” while the beta subunits are found at the “plus end” of the polymer. In cells, the minus end of a microtubule associates with the microtubule-organizing center (MTOC or centrosome) near the nucleus. From this anchored position, the microtubules radiate outward with their plus ends near the periphery of the cell. Gamma-tubulin (γ-tubulin) is localized at the MTOC and plays an important role in the process of microtubule nucleation by interacting with alpha-tubulin [<CitationRef CitationID="CR6_16">6</CitationRef>]. Gamma-tubulin combines with several proteins to form a circular structure known as the γ-tubulin ring complex (γ-TuRC). This complex acts as a scaffold for α/β-tubulin dimers to begin polymerization – the process of enucleation. It also acts as a cap for the minus end that associates with it, thus directing microtubule growth toward the (+) direction.</Para>
            <Para TextBreak="No">During polymerization, α- and β-subunits bound together as tubulin dimers are added to the growing ends of microtubules. GTP binding and hydrolysis at the exchangeable or <Emphasis Type="Italic">E-site</Emphasis> of beta-tubulin is crucial for assembly and for dynamic instability (GTP also binds to alpha-tubulin, but at the nonexchangeable or <Emphasis Type="Italic">N-site</Emphasis>). Microtubule assembly requires that GTP be bound to beta-tubulin, and this is hydrolyzed shortly after assembly. After hydrolysis, the guanine nucleotide becomes nonexchangeable, and so microtubules are mostly composed of (GTP:alpha-tubulin/GDP:beta-tubulin). The kinetics of GDP-tubulin is different from that of GTP-tubulin. Whereas GTP tubulin is stable, GDP-tubulin is prone to depolymerization. If a GDP-bound tubulin is present at the tip of a microtubule it is likely to fall off, and consequently the growing end is usually “capped” with GTP (or GDP·Pi):beta-tubulin. This GTP-cap allows microtubules, which are inherently unstable, to be stabilized by GTP (or GDP·Pi)-tubulin at the growing ends. However, when hydrolysis catches up to the tip of the microtubule and the GTP cap is lost, it begins a rapid depolymerization and shrinkage phase with the protofilaments peeling outward. This switch from growth to shrinking is called a <Emphasis Type="Italic">catastrophe</Emphasis>. GTP-bound tubulin can begin adding to the tip of the microtubule again, providing a new cap and protecting the microtubule from shrinking. This is referred to as <Emphasis Type="Italic">rescue</Emphasis>. This nonequilibrium behavior, termed <Emphasis Type="Italic">dynamic instability</Emphasis>, makes microtubules highly dynamic structures able to undergo rapid transitions between growth and shrinkage.</Para>
            <Para TextBreak="No">Dynamic instability of microtubules in vivo is regulated by interaction with other proteins. For example, during prophase of mitosis, microtubules grow out from the centrosome. If the plus end of a microtubule makes contact with a chromosome, it becomes stabilized. Otherwise rapid disassembly at the plus end ensues, and the tubulin dimers are available for growth of another microtubule.</Para>
            <Para TextBreak="No">There are numerous proteins that can interact with free tubulin dimers and/or microtubules and in so doing influence microtubule dynamics. Proteins, such as stathmin bind exclusively to tubulin dimers, thereby increasing the catastrophe rate and promoting depolymerization. By comparison, the microtubule-associated proteins (MAPs) associate with and stabilize microtubules by decreasing the frequency and duration of catastrophes and/or increasing the frequency and duration of rescues. The activities of many of these microtubule-destabilizing and microtubule-stabilizing proteins can be regulated in a cell cycle-dependent manner by phosphorylation and dephosphorylation.</Para>
            <Para TextBreak="No">Finally we should note here that while we commonly divide microtubule-targeting agents into two classes, depolymerizing/destabilzing and polymerizing/stabilizing, these properties refer to their effect at high drug concentrations and high tubulin concentrations. But we also know that in addition to these effects on the mass of tubulin, both classes of agents also suppress dynamic instability. This ability to quiet dynamics is central to the anticancer mechanisms of such drugs.</Para>
          </Section1>
          <Section1 ID="Sec3">
            <Heading>Microtubule-Depolymerizing Agents</Heading>
            <Para TextBreak="No">Microtubule-depolymerizing agents are defined by their ability to decrease the polymer mass when present at equal concentrations compared with tubulin – although as noted they impact microtubule dynamics and do this at concentrations far lower than those needed to affect the polymer mass. Three classes of microtubule-depolymerizing agents have been distinguished based on binding analysis with purified tubulin: (1) agents that competitively inhibit the binding of vinca to microtubules (the vinca alkaloids), (2) agents that competitively inhibit colchicine-binding to tubulin (the colchicine class), and (3) agents that inhibit the binding of vinca alkaloids to tubulin, but do so in a noncompetitive manner and contain a peptide-based core structure – peptides and depsipeptides [<CitationRef CitationID="CR8_16">8</CitationRef>].</Para>
            <Section2 ID="Sec4">
              <Heading>The Vinca Alkaloids</Heading>
              <Para TextBreak="No">The vinca alkaloids, a group of compounds originally derived from the common periwinkle plant include vinblastine, vincristine, vindesine, and vinorelbine. The interactions of the vinca alkaloids with both tubulin and with microtubules have been extensively characterized [<CitationRef CitationID="CR2_16">2</CitationRef>, <CitationRef CitationID="CR9_16">9</CitationRef>–<CitationRef CitationID="CR11_16">11</CitationRef>]. They bind to the β-tubulin subunit at a distinct region known as the vinca domain [<CitationRef CitationID="CR12_16">12</CitationRef>, <CitationRef CitationID="CR13_16">13</CitationRef>]. At high concentrations, vinblastine inhibits microtubule polymerization by binding to both soluble tubulin and directly to tubulin in microtubules. The evidence is clear in demonstrating that vinblastine can bind to soluble tubulin – a binding that is rapid, reversible, and relatively weak (K<Subscript>A</Subscript> ∼ 2 × 104 M<Superscript>–1</Superscript>) [<CitationRef CitationID="CR11_16">11</CitationRef>, <CitationRef CitationID="CR14_16">14</CitationRef>, <CitationRef CitationID="CR15_16">15</CitationRef>]. This binding to soluble tubulin induces a conformational change, which leads to both self-association of tubulin and increases in the affinity of vinblastine for tubulin [<CitationRef CitationID="CR9_16">9</CitationRef>, <CitationRef CitationID="CR11_16">11</CitationRef>, <CitationRef CitationID="CR16_16">16</CitationRef>]. While it has not been possible to resolve whether free vinblastine or vinblastine–tubulin aggregates bind to microtubule ends, it is clear that vinblastine binds to microtubule ends with high affinity at some 16–17 high-affinity binding sites (<Emphasis Type="Italic">k</Emphasis>
                <Subscript>d</Subscript>, 1–2 μM) present at the ends of an individual microtubule that as noted above is composed of 12–14 microfilaments [<CitationRef CitationID="CR14_16">14</CitationRef>]. Interestingly, at high concentrations, vinblastine also binds stoichiometrically with markedly reduced affinity (<Emphasis Type="Italic">k</Emphasis>
                <Subscript>d</Subscript>, 0.3 mM) to tubulin along the length of the microtubule [<CitationRef CitationID="CR17_16">17</CitationRef>, <CitationRef CitationID="CR18_16">18</CitationRef>].</Para>
              <Para TextBreak="No">The inhibition of microtubule polymerization by high concentrations of vinblastine – the property that characterizes the vinca alkaloids as depolymerizing agents – occurs through several mechanisms. Perhaps the most important is the inhibition of polymerization that results from preventing further tubulin addition consequent to the binding of vinblastine or vinblastine–tubulin aggregates to microtubule plus ends. In addition, at vinblastine levels that are far substoichiometric to the tubulin concentration drug binding to soluble tubulin induces rather than polymerization into microtubules. Finally, at high concentrations, vinblastine can bind the low-affinity sites along the microtubule surface, leading to depolymerization as tubulin dimers are “peeled away” from the microtubule ends [<CitationRef CitationID="CR17_16">17</CitationRef>]. In contrast to its effect on microtubule polymerization, high-affinity binding to the microtubule ends at the 16–17 high-affinity binding sites noted above mediates its effects on microtubule dynamics. Because this binding occurs at low vinblastine concentrations, it does not appreciably decrease the polymer mass, instead suppressing dynamic instability and treadmilling. Because of vinblastine’s high affinity for the plus ends of microtubules, concentrations as low as 0.14 μM suppress the rate of microtubule treadmilling, a measure of dynamicity, by 50% when only 1–2 vinblastine molecules are bound to the microtubule [<CitationRef CitationID="CR14_16">14</CitationRef>]. Treadmilling is a phenomenon that occurs when one end of a microfilament grows in length while the other end shrinks resulting in a section of filament seemingly “moving” across a microfilament. This is due to the constant removal of the tubulin dimers from one end of the microfilaments while dimers are constantly added at the other end. In addition to its effect on treadmilling, vinblastine suppresses growth and shortening and increases the percentage of time microtubules spend in an attenuated or paused state, neither growing nor shortening. These effects of vinblastine on dynamic instability are produced exclusively at the plus ends and are thought to be mediated by an increase in the stability of the GTP cap [<CitationRef CitationID="CR19_16">19</CitationRef>]. It has been proposed that this strengthening of the microtubule cap is brought about by a conformational change induced by the binding of even a few vinblastine molecules to the plus end of a microtubule that strengthens the affinity of the tubulin to which vinblastine is bound for adjacent tubulin subunits near the end. Interestingly, vinblastine reduces the quantity of stably bound GDP-Pi at microtubule ends [<CitationRef CitationID="CR20_16">20</CitationRef>]. Thus, the increase in cap stability may be brought about by a change in the chemical nature of the cap.</Para>
            </Section2>
            <Section2 ID="Sec5">
              <Heading>The Colchicine Class</Heading>
              <Para TextBreak="No">The interaction of colchicine with tubulin and microtubules presents another variation in the mechanisms by which microtubule-targeted drugs inhibit microtubule function. Considerable evidence has indicated that the binding of colchicine to tubulin is an unusually slow process involving a conformational change in the tubulin that locks the colchicine into a site in the form of a final-state tubulin–colchicine complex from which the colchicine very poorly dissociates [<CitationRef CitationID="CR9_16">9</CitationRef>, <CitationRef CitationID="CR21_16">21</CitationRef>].</Para>
              <Para TextBreak="No">As with the vinca alkaloids, high colchicine concentrations depolymerize microtubules, a property that assigns them to the microtubule-depolymerizing class of agents. Colchicine inhibits microtubule polymerization by binding primarily to microtubule ends rather than to the pool of soluble tubulin dimers, although it does not appear to directly bind the microtubule ends. Rather, as is thought to occur with vinblastine, colchicine first forms a poorly reversible complex with tubulin, which in turn copolymerizes together with other free tubulin dimers into the microtubule at both ends [<CitationRef CitationID="CR9_16">9</CitationRef>, <CitationRef CitationID="CR22_16">22</CitationRef>–<CitationRef CitationID="CR25_16">25</CitationRef>]. However, unlike vinblastine that selectively binds the plus ends of the microtubule, colchicine can bind at both the plus and the minus ends of the microtubule [<CitationRef CitationID="CR24_16">24</CitationRef>] but does not bind along the length of the microtubule [<CitationRef CitationID="CR26_16">26</CitationRef>].</Para>
              <Para TextBreak="No">While the incorporation of colchicine into microtubule ends can lead to microtubule depolymerization, the ends remain competent to grow and shorten. However, as with vinblastine, the ability of the ends to both grow and shorten is compromised, affecting microtubule dynamics. As with the vinca alkaloids, low substoichiometric colchicine concentrations well below the concentration of tubulin free in solution suppress microtubule dynamics [<CitationRef CitationID="CR9_16">9</CitationRef>]. Indeed, suppression of treadmilling occurs even when relatively few colchicine–tubulin complexes have been incorporated at the plus ends of microtubule [<CitationRef CitationID="CR25_16">25</CitationRef>]. Like vinblastine, the inhibition of treadmilling by colchicines occurs at steady state without affecting the mass of assembled microtubules [<CitationRef CitationID="CR25_16">25</CitationRef>, <CitationRef CitationID="CR27_16">27</CitationRef>]. Also like vinblastine, colchicine-binding to the plus ends of microtubules increases the fraction of time microtubules spend in an attenuated state, neither growing nor shortening, thus suppressing the rate and extent of microtubule growth and shortening [<CitationRef CitationID="CR28_16">28</CitationRef>].</Para>
            </Section2>
            <Section2 ID="Sec6">
              <Heading>Colchicine-Like Compounds</Heading>
              <Para TextBreak="No">Colchicine is a highly soluble alkaloid that was first isolated from the meadow saffron <Emphasis Type="Italic">Colchicum autumnale</Emphasis> and has been widely used for the treatment of gout [<CitationRef CitationID="CR29_16">29</CitationRef>]. However, because its toxicity profile prevented colchicine’s widespread use investigators from numerous disciplines have searched for simplified, less toxic analogs. The search has led to the identification of numerous compounds that are either structurally similar or that bind to the colchicine-binding site and are considered functionally similar. One such compound is combretastatin A-4, originally isolated from the African willow tree <Emphasis Type="Italic">Combretum caffrum</Emphasis> and structurally related to colchicines. In vitro studies have shown that combretastatin A-4 and several related analogs inhibit tubulin polymerization and interact with tubulin at or near the colchicine-binding site [<CitationRef CitationID="CR30_16">30</CitationRef>]. The combretastatins contain two phenyl rings linked by a two-carbon bridge, with several methoxy substitutions on the ring system [<CitationRef CitationID="CR31_16">31</CitationRef>]. Because of its limited water solubility the clinical development of combretastatin A-4 was not possible, and this led to the synthesis of combretastatin A-4 phosphate (CA-4-P), a prodrug that rapidly dephosphorylates in vivo to the active compound combretastatin A-4 [<CitationRef CitationID="CR32_16">32</CitationRef>]. In animal models, CA-4-P leads to rapid and selective disruption of the tumor vasculature resulting in hemorrhagic necrosis of tumors [<CitationRef CitationID="CR33_16">33</CitationRef>]. The mechanism of this disruption of the tumor vasculature has been debated, with some investigators advocating apoptosis of proliferating endothelial cells as the cause and others suggesting that by inhibiting endothelial cell migration CA-4-P inhibits angiogenesis [<CitationRef CitationID="CR33_16">33</CitationRef>, <CitationRef CitationID="CR34_16">34</CitationRef>].</Para>
              <Para TextBreak="No">Another antimitotic compound that binds to the colchicine site of tubulin is 2-ME, a naturally occurring metabolite of estradiol, which is normally excreted in the urine [<CitationRef CitationID="CR35_16">35</CitationRef>]. 2-ME competitively binds to the colchicine-binding site of β-tubulin, and depending on the reaction conditions it either inhibits tubulin polymerization or results in the formation of a polymer with altered stability [<CitationRef CitationID="CR36_16">36</CitationRef>]. While its principal mode of toxicity is likely inhibition of tubulin polymerization with impaired microtubule trafficking and mitotic arrest, the thought that 2-ME could inhibit angiogenesis was a principal catalyst for its clinical development not as a microtubule-targeting agent but as an “antiangiogenic” agent [<CitationRef CitationID="CR35_16">35</CitationRef>, <CitationRef CitationID="CR37_16">37</CitationRef>].</Para>
              <Para TextBreak="No">A final member of this class that has undergone clinical development is mivobulin isethionate (CI-980), a synthetic water-soluble compound that competitively binds tubulin at the colchicine-binding site and inhibits tubulin polymerization [<CitationRef CitationID="CR38_16">38</CitationRef>]. Interest in this compound was heightened by its broad spectrum of activity in murine and human tumor models that were cross-resistant to a wide range of chemotherapeutics [<CitationRef CitationID="CR39_16">39</CitationRef>].</Para>
            </Section2>
            <Section2 ID="Sec7">
              <Heading>Peptides and Depsipeptides</Heading>
              <Para TextBreak="No">The dolastatin peptides, originally isolated from the small Indian Ocean sea hare Dollabella auricularia are small linear peptide molecules that interfere with tubulin by binding at the vinca/peptide region. Interestingly, speculation that the dolastatins were microbial products and not actually produced by D. auricularia has been confirmed. The assortment of amino acids in the peptides comprising the dolastatins pointed to a probable cyanobacterial (blue-green “algae”) origin now identified as a marine cyanobacteria known to be grazed by <Emphasis Type="Italic">D. auricularia</Emphasis>.</Para>
              <Para TextBreak="No">Although vinblastine and dolastatin have similar quantitative effects on assembly reactions, dolastatin 10 has been shown to accumulate to higher levels and remain in cells longer – an observation ascribed to differences in the interactions of the two drugs with tubulin, with dolastatin having much higher affinity [<CitationRef CitationID="CR40_16">40</CitationRef>]. Thus, if one is to preserve drug-induced structures by HPLC, vinblastine but not dolastatin must be present in the column equilibration buffer [<CitationRef CitationID="CR41_16">41</CitationRef>, <CitationRef CitationID="CR42_16">42</CitationRef>]. Furthermore, underscoring dolastatin’s affinity for tubulin, an unbound dolastatin 10 peak can only be detected when the drug:tubulin ratio is greater than one. Moreover, the apparent Ka value for dolastatin 10 (3.8 × 10<Superscript>7</Superscript> M<Superscript>–1</Superscript>) [<CitationRef CitationID="CR42_16">42</CitationRef>] is 21-fold higher than that obtained for vinblastine (1.8 × 10<Superscript>6</Superscript> M<Superscript>–1</Superscript>) [<CitationRef CitationID="CR43_16">43</CitationRef>]. At the cellular level, these differences result in markedly higher retention of dolastatin 10 as compared with vinblastine.</Para>
              <Para TextBreak="No">Dolastatin 10, a four amino acid peptide (dolavaline, valine, dolaisoleuine, dolaproine) linked to a complex primary amine (dolaphenine), is cytotoxic at subnanomolar concentrations [<CitationRef CitationID="CR12_16">12</CitationRef>]. Studies have shown that the dolaisoleuine amino acid residue is critical for the inhibition of tubulin polymerization but that the dolaproine or dolavaline amino acids can be modified without inhibiting tubulin polymerization [<CitationRef CitationID="CR44_16">44</CitationRef>, <CitationRef CitationID="CR45_16">45</CitationRef>]. For example, auristatin PE (TZT-1027), a structurally modified dolastatin 10 analog, has a phenylalanine in place of the terminal dolaphenine [<CitationRef CitationID="CR46_16">46</CitationRef>].</Para>
              <Para TextBreak="No">Dolastatin 10 inhibits microtubule assembly and polymerization of tubulin [<CitationRef CitationID="CR44_16">44</CitationRef>]. Because dolastatin 10 noncompetitively inhibits vinblastine-binding, it was originally thought to bind at the vinca alkaloid site; however, it was subsequently shown to inhibit binding of rhizoxin and phomopsin A to tubulin, indicating that it binds to the rhizoxin/maytansine region on tubulin [<CitationRef CitationID="CR47_16">47</CitationRef>]. Studies of auristatin PE have shown that it inhibits tubulin polymerization similar to dolastatin 10 [<CitationRef CitationID="CR48_16">48</CitationRef>, <CitationRef CitationID="CR49_16">49</CitationRef>].</Para>
            </Section2>
          </Section1>
          <Section1 ID="Sec8">
            <Heading>The Mechanism of Action of Paclitaxel and Other Microtubule-Stabilizing Compounds</Heading>
            <Para TextBreak="No">In 1967, Monroe Wall working with extracts from the bark of the yew tree (<Emphasis Type="Italic">Taxus brevifolia</Emphasis>) named a compound “taxol” based on its source and because it was an alcohol. Now known by the generic name paclitaxel and the trade name Taxol<Superscript>®</Superscript>, it was first described in a landmark study by Wall, Mansukh Wani, and their colleagues that began the era of microtubule-stabilizing agents – an era that only became apparent when studies conducted by Horwitz and her colleagues in 1979 showed it was able to increase the rate and extent of microtubule assembly in vitro and to stabilize microtubules in vitro and in cells [<CitationRef CitationID="CR50_16">50</CitationRef>–<CitationRef CitationID="CR52_16">52</CitationRef>]. The first experiments demonstrated that paclitaxel at nanomolar concentrations inhibited the replication of HeLa cells by blocking cells in metaphase. Previously studied drugs such as colchicine and the vinca alkaloids were known to block cells in mitosis, but unlike those agents, paclitaxel treatment resulted in microtubules’ reorganization with the appearance of distinct microtubule bundles.</Para>
            <Para TextBreak="No">The formation of <Emphasis Type="Italic">stable microtubule bundles</Emphasis>, now recognized as diagnostic of microtubule stabilization, suggested that paclitaxel enhanced microtubule assembly and stabilized existing microtubules. These hypotheses were confirmed by several experiments including early studies showing paclitaxel-stabilized microtubules against cold-induced depolymerization and augmented assembly of microtubules at steady state by promoting the elongation of existing microtubules as well as spontaneous nucleation of new microtubules [<CitationRef CitationID="CR53_16">53</CitationRef>]. In the absence of paclitaxel, polymerization occurred after a lag period of 3–4 min while in the presence of paclitaxel, the lag period was eliminated, indicating that paclitaxel enhanced the initiation phase of microtubule polymerization [<CitationRef CitationID="CR51_16">51</CitationRef>]. Furthermore, paclitaxel polymerized tubulin even at cold temperatures and in the absence of MAPs and GTP. The microtubules that formed in the presence of paclitaxel were resistant to cold (4°C) and Ca<Superscript>2+</Superscript>-induced depolymerization. Paclitaxel also affects microtubule structure, reducing the number of microfilaments from a normal average of 13 to an average of 12 [<CitationRef CitationID="CR54_16">54</CitationRef>].</Para>
            <Para TextBreak="No">Sedimentation assays to assess the binding of [<Superscript>3</Superscript>H]paclitaxel to microtubule protein [<CitationRef CitationID="CR55_16">55</CitationRef>] found that although both podophyllotoxin and vinblastine were able to inhibit the binding of [<Superscript>3</Superscript>H]paclitaxel to microtubule protein unlike unlabeled paclitaxel, which competitively displaced [<Superscript>3</Superscript>H]paclitaxel from microtubules, podophyllotoxin and vinblastine did not. Although the latter two drugs reduced the mass of paclitaxel-stabilized microtubules, the specific activity of bound [<Superscript>3</Superscript>H]paclitaxel remained constant. This data was consistent with competition between paclitaxel and either podophyllotoxin or vinblastine for different forms of tubulin (the dimeric or soluble form and the polymeric or microtubule form) and not competition for a single binding site. Finally the observation that preassembled microtubules bound [<Superscript>3</Superscript>H]paclitaxel with the same stoichiometry as microtubules assembled in the presence of [<Superscript>3</Superscript>H]paclitaxel led to the conclusion that paclitaxel bound specifically and reversibly to the polymerized form of tubulin with a stoichiometry approaching unity [<CitationRef CitationID="CR56_16">56</CitationRef>]. Subsequent studies identified the paclitaxel-binding site in the β-tubulin subunit of intact microtubules, a conclusion that is now widely accepted after having been confirmed by electron crystallography [<CitationRef CitationID="CR57_16">57</CitationRef>]. There is no evidence that paclitaxel binds to soluble tubulin dimer.</Para>
            <Para TextBreak="No">In contrast to cells exposed to microtubule-destabilizing agents, cells exposed to high concentrations of paclitaxel present with an increase in the mass of microtubule polymer and microtubule bundle formation in interphase cells. Bundle formation has become a hallmark of paclitaxel-binding and is now recognized as a property of microtubule stabilization [<CitationRef CitationID="CR52_16">52</CitationRef>]. However, as with the microtubule-destabilizing agents an effect on the polymer mass occurs only above a threshold concentration of the drug. At paclitaxel concentrations below 10 nM, there is no obvious effect on polymer mass and only a fraction of the paclitaxel-binding sites on the microtubule is occupied; instead the principal drug effect is suppression of microtubule dynamics [<CitationRef CitationID="CR58_16">58</CitationRef>, <CitationRef CitationID="CR59_16">59</CitationRef>]. Because this effect at low paclitaxel concentrations is similar to that observed with low concentrations of vinblastine and other microtubule-destabilizing agents it has been suggested that both drug classes block mitosis by decreasing the dynamics of spindle microtubules. However, the two drug classes exhibit different mitotic effects at low concentrations [<CitationRef CitationID="CR60_16">60</CitationRef>]. Microtubule-stabilizing drugs, including paclitaxel and the epothilones, induce multipolar spindles but cannot sustain a mitotic block resulting in aneuploidy as cells exit from an aberrant mitosis [<CitationRef CitationID="CR60_16">60</CitationRef>, <CitationRef CitationID="CR61_16">61</CitationRef>]. In contrast, destabilizing drugs such as the vinca alkaloids do not lead to aneuploidy at low concentrations [<CitationRef CitationID="CR61_16">61</CitationRef>].</Para>
          </Section1>
          <Section1 ID="Sec9">
            <Heading>The Interaction of Paclitaxel and Microtubules</Heading>
            <Para TextBreak="No">Early studies employing photoaffinity labeling with initial [<Superscript>3</Superscript>H]-paclitaxel demonstrated that paclitaxel binds specifically to the beta-subunit of tubulin [<CitationRef CitationID="CR56_16">56</CitationRef>, <CitationRef CitationID="CR62_16">62</CitationRef>–<CitationRef CitationID="CR66_16">66</CitationRef>]. A more detailed definition of the contact sites between beta-tubulin and paclitaxel became possible when paclitaxel analogs bearing photoreactive groups became available. These studies led to the isolation of photolabeled beta-tubulin peptides containing amino-acid residues 1–31 [<CitationRef CitationID="CR62_16">62</CitationRef>], 217–233 [<CitationRef CitationID="CR63_16">63</CitationRef>], and Arg282 [<CitationRef CitationID="CR65_16">65</CitationRef>]. Eventually, excellent agreement was found between the binding site predicted using the various photoaffinity analogs and that determined by electron crystallography [<CitationRef CitationID="CR67_16">67</CitationRef>].</Para>
          </Section1>
          <Section1 ID="Sec10">
            <Heading>Nontaxane Microtubule-Stabilizing Drugs</Heading>
            <Para TextBreak="No">The clinical success of paclitaxel first and then docetaxel (Taxotere<Superscript>®</Superscript>) in the treatment of cancer patients catalyzed an extensive search for additional microtubule-stabilizing compounds. Different approaches led to the identification of several natural products unrelated to the taxanes that were found to stabilize microtubules [<CitationRef CitationID="CR68_16">68</CitationRef>–<CitationRef CitationID="CR70_16">70</CitationRef>]. The first and most extensively characterized were epothilones A and B, two novel polyketide natural products isolated from the fermentation broth of a soil Myxobacterium, <Emphasis Type="Italic">Sorangium cellulosum</Emphasis> strain 90. As with taxol, the epothilones were found to polymerize tubulin, form microtubule bundles, and arrest cells in mitosis [<CitationRef CitationID="CR68_16">68</CitationRef>]. Compared with paclitaxel, both epothilones were reported to be more potent in promoting microtubule assembly in vitro. The identification of the epothilones suggested that additional agents with microtubule stabilizing properties likely existed, an expectation that was affirmed by the isolation of discodermolide from <Emphasis Type="Italic">Discodermia dissolute</Emphasis>, a Caribbean sponge. Like the epothilones, discodermolide was shown to induce microtubule assembly in vitro, microtubule bundling, and mitotic arrest [<CitationRef CitationID="CR69_16">69</CitationRef>, <CitationRef CitationID="CR71_16">71</CitationRef>, <CitationRef CitationID="CR72_16">72</CitationRef>]. Subsequent studies led to the isolation of eleutherobin, a diterpene glycoside, from an <Emphasis Type="Italic">Eleutherobia</Emphasis> species of soft, red-colored coral found near Western Australian, the closely related sarcodictyins and finally the laulimalides, complex macrolide compounds isolated from the marine sponge <Emphasis Type="Italic">Cacospongia mycofijiensis</Emphasis> [<CitationRef CitationID="CR73_16">73</CitationRef>–<CitationRef CitationID="CR75_16">75</CitationRef>]. With the exception of laulimalide, these agents can stabilize and competitively inhibit the binding of [<Superscript>3</Superscript>H]-paclitaxel to microtubules [<CitationRef CitationID="CR72_16">72</CitationRef>, <CitationRef CitationID="CR76_16">76</CitationRef>]. This has been explained by proposing that all drugs except laulimalide interact at the same or an overlapping binding domain as paclitaxel on beta-tubulin, with laulimalide possibly binding to α-tubulin [<CitationRef CitationID="CR77_16">77</CitationRef>]. However, emerging evidence from electron crystallographic studies might challenge the extent to which the binding sites overlap. While all of these agents can stabilize mammalian microtubules, this property might be too crude or imprecise to discriminate binding sites. Identifying/characterizing the binding site on the microtubule may eventually be of value in the design of analogs or even synthetic compounds targeting microtubules.</Para>
          </Section1>
          <Section1 ID="Sec11">
            <Heading>The Role of Microtubule Stability and Dynamics in Drug Sensitivity</Heading>
            <Para TextBreak="No">Selection of cell lines resistant to microtubule targeting agents has provided insight into drug action and intrinsic drug sensitivity. Early selections employed microtubule-destabilizing agents since these had been discovered first and approved for clinical use. These selections led to the isolation of resistant cells harboring mutations in tubulin, manifested by alterations in protein migration or cells with reduced intracellular drug concentrations mediated by the multidrug transporter, P-glycoprotein [<CitationRef CitationID="CR78_16">78</CitationRef>, <CitationRef CitationID="CR79_16">79</CitationRef>]. The advent of paclitaxel, and its clinical success, followed by the realization of its limitations and the occurrence of resistance then led to widespread interest and the isolation of cells resistant to paclitaxel and then to other microtubule-stabilizing agents. The expectation was that given the drug’s specificity for its target, tubulin, mutations would emerge that would impair rug binding and identify the binding site. However, in the majority of resistant cell lines, mutations mapping to putative drug binding sites that would interfere with drug binding were not found [<CitationRef CitationID="CR80_16">80</CitationRef>–<CitationRef CitationID="CR82_16">82</CitationRef>]. Instead the mutations or adaptations found were such that they affected microtubule stability and dynamics, and in turn, drug sensitivity. While unexpected, this outcome might be explained by considering the fact that because tubulin is an essential cellular protein the mutations it can “tolerate” might be constrained. Specifically, mutations that arise in drug-resistant cells must both confer resistance to the selecting drug while not interfering with areas essential for the function of tubulin, since cellular survival would not be possible. The high degree of sequence conservation across species is an evidence that a large portion of the protein is essential, and thus possibly “off limits” to the emergence of a mutation.</Para>
            <Para TextBreak="No">In this context, two models have been proposed to help us understand the relationship between resistance to microtubule-targeting agents and the importance of microtubule stability and dynamics. The first hypothesis posits that under normal circumstances microtubule stability or polymerization is maintained within a limited range. According to this model, the <Emphasis Type="Italic">intrinsic sensitivity</Emphasis> to a microtubule-targeting agent depends on the basal level of microtubule stability/polymerization [<CitationRef CitationID="CR83_16">83</CitationRef>–<CitationRef CitationID="CR85_16">85</CitationRef>]. Thus, in a cell with a higher basal level of polymerized tubulin (microtubules) it is easier for a microtubule-stabilizing agent to achieve its goal, and such a cell is more sensitive to a microtubule-stabilizing agent. One should note that since a drug such as paclitaxel preferentially (exclusively) binds microtubules (polymerized tubulin) – not tubulin dimers – a cell with a more stable polymer presents more sites for drug binding and would be more sensitive to paclitaxel. Conversely, cells with less stable or polymerized tubulin (i.e., microtubules) should be resistant to drugs such as paclitaxel, but have greater sensitivity to depolymerizing agents such as vinblastine whose goal is to destabilize microtubules and whose target is tubulin dimers. The model also offers a potential explanation for why low paclitaxel concentrations are required by some paclitaxel-resistant cell lines for normal growth – the cells require low concentrations of paclitaxel to stabilize a microtubule that is otherwise too unstable. Remembering that in these “drug-dependent cells”, the acquired mutation emerged while cells were kept in a medium containing paclitaxel, one can posit that the mutation (in a site other than the paclitaxel-binding site) perturbed polymer stability to such an extent – actually the polymer is so hypostable – that normal microtubule function is only possible in the presence of some “stabilizing drug”.</Para>
            <Para TextBreak="No">A second model evolved from the observation that at low concentrations both microtubule-stabilizing and -destabilizing agents impact microtubule <Emphasis Type="Italic">dynamics</Emphasis> without affecting the microtubule polymer mass [<CitationRef CitationID="CR58_16">58</CitationRef>, <CitationRef CitationID="CR86_16">86</CitationRef>, <CitationRef CitationID="CR87_16">87</CitationRef>]. In a manner analogous to the model that implicates tubulin stability (in the form of microtubules) as crucial for drug sensitivity, microtubule dynamics is also crucial for drug sensitivity: increased dynamics confers resistance to microtubule-stabilizing agents while reduced dynamics underlies insensitivity to destabilizing compounds. Therefore, in paclitaxel-resistant cell lines, the equilibrium is shifted in favor of highly dynamic microtubules antagonizing the effects of paclitaxel [<CitationRef CitationID="CR59_16">59</CitationRef>, <CitationRef CitationID="CR86_16">86</CitationRef>–<CitationRef CitationID="CR88_16">88</CitationRef>]. An increase in microtubule dynamics also provides a survival advantage to a cell challenged with a microtubule-stabilizing drug such as paclitaxel.</Para>
          </Section1>
          <Section1 ID="Sec12">
            <Heading>Resistance to Microtubule-Stabilizing Agents</Heading>
            <Para TextBreak="No">A full discussion of resistance mechanisms is beyond the scope of this chapter and the reader is referred to other reviews [<CitationRef CitationID="CR89_16">89</CitationRef>]. To date, the evidence accumulated has been obtained principally with paclitaxel, and to a lesser extent with the epothilones, and colchicines as well as other destabilizing agents. However, it is likely that these changes/mechanisms apply to varying extents to all microtubule-stabilizing agents. The following mechanisms have been identified or proposed: (1) changes in the absolute or relative expression levels of tubulin isotypes; (2) tubulin mutations that impact longitudinal/lateral interactions and can alter microtubule dynamics; (3) ubulin mutations that affect either binding of regulatory proteins or GTP; (4) posttranslational modifications that affect the binding of regulatory protein; (5) altered expression and posttranslational modifications of proteins that regulate the dynamics/stability of the microtubules; (6) altered drug binding to the microtubule often secondary to acquired mutations; and (7) alterations in signaling pathways.</Para>
          </Section1>
          <Section1 ID="Sec13">
            <Heading>Role of Microtubule Targeting Agents in the Treatment of Castration-Resistant Prostate Cancer</Heading>
            <Para TextBreak="No">Castration-resistant prostate cancer (CRPC) is defined as a rising serum prostate-specific antigen (PSA) despite castrate levels of testosterone. CRPC is an incurable condition projected to cause almost 27,360 deaths in America alone in 2009 [<CitationRef CitationID="CR90_16">90</CitationRef>]. The microtubule-stabilizing agent docetaxel with prednisone is the current first-line, standard of care for advanced prostate cancer resistant to androgen-ablative therapy [<CitationRef CitationID="CR91_16">91</CitationRef>, <CitationRef CitationID="CR92_16">92</CitationRef>]. This is based on two landmark phase III trials published in the New England Journal of Medicine in 2004 in which docetaxel-based chemotherapy was shown to provide both a survival and palliative advantage for patients with CRPC when compared with mitoxantrone and prednisone [<CitationRef CitationID="CR91_16">91</CitationRef>, <CitationRef CitationID="CR92_16">92</CitationRef>]. While a detailed discussion of the role of taxanes for CRPC is presented elsewhere in this publication, it is important to note that the survival advantage of docetaxel over mitoxantrone is only 2–3 months [<CitationRef CitationID="CR91_16">91</CitationRef>, <CitationRef CitationID="CR92_16">92</CitationRef>], and a significant proportion of patients with castration-resistant prostate cancer become refractory to taxane-based treatments [<CitationRef CitationID="CR93_16">93</CitationRef>]. The efficacy of taxane-based therapies for CRPC is limited by the development of drug resistance. Taxane resistance is mediated predominantly, but not exclusively, by overexpression of the transmembrane transporter P-glycoprotein, leading to the multidrug resistance phenotype [<CitationRef CitationID="CR94_16">94</CitationRef>]. Thus, novel microtubule-targeted agents are needed that can be used in the setting of taxane-refractory, castration-resistant prostate cancer. Such agents include the epothilone class of drugs as well as the semisynthetic taxoid compound XRP6258 (cabazitaxel, Jevtana®, Sanofi-Aventis). The subsequent sections of this chapter focus on the clinical development of these agents.</Para>
          </Section1>
          <Section1 ID="Sec14">
            <Heading>Epothilones in Castration-Resistant Prostate Cancer</Heading>
            <Para TextBreak="No">Epothilones are macrolides that were isolated from the myxobacterium <Emphasis Type="Italic">Sorangium cellulosum</Emphasis> [<CitationRef CitationID="CR94_16">94</CitationRef>]<Emphasis Type="Italic">.</Emphasis> These nontaxane microtubule-stabilizing agents in clinical development include epothilone B (patupilone; EPO906, Novartis), ixabepilone (azaepothilone B; BMS-247550, Bristol-Myers Squibb), BMS-310705 (a water-soluble epothilone B derivative, Bristol-Myers Squibb), ZK-EPO (ZK-219477, a third-generation epothilone B derivative, Schering AG), and KOS-862 (epothilone D; desoxyepothilone B, Kosan Biosciences) [<CitationRef CitationID="CR94_16">94</CitationRef>]. Similar to the taxanes, the epothilones promote microtubule stabilization and lead to mitotic arrest at the G2/M phase of the cell cycle, ultimately inducing apoptosis [<CitationRef CitationID="CR94_16">94</CitationRef>]. However, it has been shown that the epothilones differ from the taxanes with respect to the binding site on β-tubulin and thus, the epothilones represent a distinct class of antimicrotubule agents [<CitationRef CitationID="CR96_16">96</CitationRef>].</Para>
            <Section2 ID="Sec15">
              <Heading>Preclinical Data</Heading>
              <Para TextBreak="No">The epothilones have demonstrated potent antitumor activity in vitro as well as in experimental animal models of prostate cancer [<CitationRef CitationID="CR93_16">93</CitationRef>]. In cell culture assays utilizing human prostate cancer cell lines DU145 and PC-3M, epothilone B (patupilone; EPO906) and aza-epothilone B (ixabepilone<Superscript>®</Superscript>; BMS-247550) have demonstrated more potent cytotoxicity than paclitaxel (Taxol<Superscript>®</Superscript>) [<CitationRef CitationID="CR97_16">97</CitationRef>]. In athymic murine xenograft models of castrate-resistant prostate cancer using these same two human prostate cancer cell lines, administration of epothilone B (patupilone) was associated with the inhibition of tumor growth, followed by sustained regression [<CitationRef CitationID="CR98_16">98</CitationRef>].</Para>
              <Para TextBreak="No">Preclinical studies have shown that epothilones have cytotoxic activity against taxane-resistant tumor models and thus lack cross-resistance with the taxanes [<CitationRef CitationID="CR93_16">93</CitationRef>]. Possible explanations for this include the minimal effect on epothilone cytotoxicity generated by either P-glycoprotein overexpression or mutations in β-tubulin, both of which are known to mediate taxane resistance [<CitationRef CitationID="CR99_16">99</CitationRef>–<CitationRef CitationID="CR101_16">101</CitationRef>].</Para>
            </Section2>
            <Section2 ID="Sec16">
              <Heading>Phase I Clinical Trials of the Epothilones</Heading>
              <Para TextBreak="No">Multiple dosing schedules of patupilone and its semisynthetic derivative ixabepilone (BMS – 247550) have been studied in phase I trials. The toxicity profiles of the epothilones are diverse and depend on the particular agent and administration schedule [<CitationRef CitationID="CR94_16">94</CitationRef>] Table <InternalRef RefID="Tab1">16.1</InternalRef>.<Table Float="Yes" ID="Tab1">
                  <Caption Language="En">
                    <CaptionNumber>Table 16.1</CaptionNumber>
                    <CaptionContent>
                      <SimplePara>Epothilones in clinical development</SimplePara>
                    </CaptionContent>
                  </Caption>
                  <tgroup cols="5">
                    <colspec colname="c1" colnum="1"/>
                    <colspec colname="c2" colnum="2"/>
                    <colspec colname="c3" colnum="3"/>
                    <colspec colname="c4" colnum="4"/>
                    <colspec colname="c5" colnum="5"/>
                    <thead>
                      <row>
                        <entry colname="c1">
                          <SimplePara>Epothilones</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>Other names</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>Characteristics</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>Clinical phase of development</SimplePara>
                        </entry>
                        <entry colname="c5">
                          <SimplePara>Manufacturer</SimplePara>
                        </entry>
                      </row>
                    </thead>
                    <tbody>
                      <row>
                        <entry colname="c1">
                          <SimplePara>Ixabepilone</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>BMS247550</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>Aza-epothilone B</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>FDA approval for breast cancer</SimplePara>
                        </entry>
                        <entry colname="c5">
                          <SimplePara>Bristol-Myers Squibb</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c1">
                          <SimplePara>Patupilone</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>EPO906</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>Epothilone B (natural epothilone)</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>Phase III</SimplePara>
                        </entry>
                        <entry colname="c5">
                          <SimplePara>Novartis</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c1">
                          <SimplePara>BMS-310705</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>NA</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>Water-soluble, semisynthetic analog of epothilone B</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>Phase I (terminated)</SimplePara>
                        </entry>
                        <entry colname="c5">
                          <SimplePara>Bristol-Myers Squibb</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c1">
                          <SimplePara>KOS-862</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>NA</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>Epothilone D (deoxyepothilone B)</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>Phase II (terminated)</SimplePara>
                        </entry>
                        <entry colname="c5">
                          <SimplePara>Bristol-Myers Squibb</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c1">
                          <SimplePara>KOS-1584</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>NA</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>9,10-didehydroepothilone D</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>Phase I</SimplePara>
                        </entry>
                        <entry colname="c5">
                          <SimplePara>Roche and Bristol-Myers Squibb</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c1">
                          <SimplePara>ZK-EPO</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>NA</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>Synthetic epothilone</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>Phase II</SimplePara>
                        </entry>
                        <entry colname="c5">
                          <SimplePara>Schering</SimplePara>
                        </entry>
                      </row>
                    </tbody>
                  </tgroup>
                  <tfooter>
                    <SimplePara>Adapted with permission from Macmillan Publishers Ltd [97]. Copyright 2009</SimplePara>
                    <SimplePara>
                      <Emphasis Type="Italic">NA</Emphasis> not available</SimplePara>
                  </tfooter>
                </Table>
              </Para>
              <Para TextBreak="No">Patupilone has been evaluated as a single agent in several regimens, including dosing once every 3 weeks [<CitationRef CitationID="CR102_16">102</CitationRef>] with a maximum tolerated dosage (MTD) of 8 mg/m<Superscript>2</Superscript>, and a weekly schedule [<CitationRef CitationID="CR103_16">103</CitationRef>] with an MTD of 2.5 mg/m<Superscript>2</Superscript>. The most common dose-limiting toxicities for both schedules of patupilone were diarrhea and fatigue [<CitationRef CitationID="CR93_16">93</CitationRef>, <CitationRef CitationID="CR94_16">94</CitationRef>]. Multiple phase I studies of ixabepilone (BMS-247550) have been reported in the literature and two of them will be discussed here. An accelerated titration phase I trial of BMS-247550 in 17 patients was reported in 2005 [<CitationRef CitationID="CR104_16">104</CitationRef>]. BMS-247550 was administered as a 1-h infusion every 3 weeks; all patients received prophylaxis for hypersensitivity reactions with steroids and histamine antagonists. The MTD of every 3-week administration of BMS-247550 in this study was 40 mg/m<Superscript>2</Superscript> with neutropenia being the dose-limiting toxicity [<CitationRef CitationID="CR104_16">104</CitationRef>]. A subsequent accelerated dose-escalation phase I trial of ixabepilone was reported in 2007 in which BMS-247550 was given as a 1-h infusion every 3 weeks to patients with advanced solid tumors or relapsed/refractory non-Hodgkin’s lymphoma. Sixty-one patients were enrolled and the most common dose-limiting toxicities were neutropenia, stomatitis/pharyngitis, myalgia, and arthralgia. The MTD of ixabepilone in this study was determined to be 50 mg/m<Superscript>2</Superscript> when given as a 1-h infusion every 3 weeks [<CitationRef CitationID="CR105_16">105</CitationRef>]. A 3-h infusion time is recommended, because a higher risk for neurotoxicity was observed with the shorter infusion time [<CitationRef CitationID="CR96_16">96</CitationRef>, <CitationRef CitationID="CR104_16">104</CitationRef>]. The current FDA-approved dose and schedule for ixabepilone in phase II trials is 40 mg/m<Superscript>2</Superscript> I.V. over 3 h, given once every 3 weeks [<CitationRef CitationID="CR96_16">96</CitationRef>]. The most common grade 3 or 4 toxicity associated with single-agent ixabepilone at 40-mg/m<Superscript>2</Superscript> dose every 3 weeks is neutropenia [<CitationRef CitationID="CR96_16">96</CitationRef>], although it should be noted that grade 3 peripheral sensory neuropathy was also commonly encountered. Phase I clinical trials have shown that single-agent patupilone and ixabepilone have activity against castration-resistant prostate cancer, and this finding has led to subsequent phase II evaluations of these two drugs.</Para>
            </Section2>
            <Section2 ID="Sec17">
              <Heading>Phase II Clinical Trials of the Epothilones for CRPC</Heading>
              <Para TextBreak="No">To date, ixabepilone and patupilone have provided the most convincing data regarding clinical activity in patients with castration-resistant prostate cancer [<CitationRef CitationID="CR93_16">93</CitationRef>]. The phase II SWOG0111 clinical trial [<CitationRef CitationID="CR106_16">106</CitationRef>] evaluated ixabepilone (at 40 mg/m<Superscript>2</Superscript> over 3 h once every 3 weeks) in 42 patients [median age, 73 years; median prostate specific antigen (PSA) level 111 ng/mL] with chemotherapy-naïve, metastatic castration-resistant prostate cancer [<CitationRef CitationID="CR106_16">106</CitationRef>]. The primary objective was to assess the proportion of patients achieving a ≥50% reduction in PSA levels in response to ixabepilone. Of the 42 patients treated with ixabepilone, 14 patients (33%) had a confirmed PSA response; the majority of these patients (72%) had PSA declines of greater than 80%, and two patients achieved undetectable PSA (&lt;0.2 ng/mL) [<CitationRef CitationID="CR106_16">106</CitationRef>]. Among the 20 patients with measurable disease, one patient had an unconfirmed complete response and two patients had unconfirmed partial responses [<CitationRef CitationID="CR106_16">106</CitationRef>]. There were no confirmed objective complete responses. The estimated progression-free survival was 6 months (95% CI, 4–8 months), and the median survival was 18 months (95% CI, 13–24 months). All grade 4 toxicities were neutropenia or leukopenia. The most frequent grade 3 adverse events were neuropathy, hematologic toxicity, flu-like symptoms, and infection. The SWOG0111 trial has thus demonstrated that single-agent ixabepilone has activity in chemotherapy-naive metastatic CRPC (Table <InternalRef RefID="Tab2">16.2</InternalRef>).<Table Float="Yes" ID="Tab2">
                  <Caption Language="En">
                    <CaptionNumber>Table 16.2</CaptionNumber>
                    <CaptionContent>
                      <SimplePara>Phase II clinical trials of epothilones in patients with metastatic castration-resistant prostate cancer</SimplePara>
                    </CaptionContent>
                  </Caption>
                  <tgroup cols="6">
                    <colspec colname="c1" colnum="1"/>
                    <colspec colname="c2" colnum="2"/>
                    <colspec colname="c3" colnum="3"/>
                    <colspec colname="c4" colnum="4"/>
                    <colspec colname="c5" colnum="5"/>
                    <colspec colname="c6" colnum="6"/>
                    <thead>
                      <row>
                        <entry colname="c1"/>
                        <entry colname="c2"/>
                        <entry colname="c3"/>
                        <entry colname="c4"/>
                        <entry nameend="c6" namest="c5">
                          <SimplePara>Response rate (%)</SimplePara>
                        </entry>
                      </row>
                    </thead>
                    <tbody>
                      <row>
                        <entry colname="c1">
                          <SimplePara>Agents</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>References</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>Clinical setting of CRPC</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>Number of patients</SimplePara>
                        </entry>
                        <entry colname="c5">
                          <SimplePara>PSA decline 50%</SimplePara>
                        </entry>
                        <entry colname="c6">
                          <SimplePara>Tumor shrinkage</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c1">
                          <SimplePara>Ixabepilone (40 mg/m<Superscript>2</Superscript> Q3 weeks)</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>Hussain et al. [<CitationRef CitationID="CR106_16">106</CitationRef>]</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>Chemotherapy-naive</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>42</SimplePara>
                        </entry>
                        <entry colname="c5">
                          <SimplePara>33</SimplePara>
                        </entry>
                        <entry colname="c6">
                          <SimplePara>ND</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c1">
                          <SimplePara>Ixabepilone (35 mg/m<Superscript>2</Superscript> Q3 weeks)</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>Galsky et al. [<CitationRef CitationID="CR107_16">107</CitationRef>]</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>Chemotherapy-naive</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>45</SimplePara>
                        </entry>
                        <entry colname="c5">
                          <SimplePara>48</SimplePara>
                        </entry>
                        <entry colname="c6">
                          <SimplePara>32</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c1">
                          <SimplePara>Ixabepilone (35 mg/m<Superscript>2</Superscript> Q3 weeks) with estramustine (280 mg TID on D1-5)</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>Galsky et al. [<CitationRef CitationID="CR107_16">107</CitationRef>]</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>Chemotherapy-naive</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>47</SimplePara>
                        </entry>
                        <entry colname="c5">
                          <SimplePara>69</SimplePara>
                        </entry>
                        <entry colname="c6">
                          <SimplePara>48</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c1">
                          <SimplePara>Ixabepilone (35 mg/m<Superscript>2</Superscript> Q3 weeks) or mitoxantrone (14 mg/m<Superscript>2</Superscript> Q3 weeks) with prednisone</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>Rosenberg et al. [<CitationRef CitationID="CR108_16">108</CitationRef>]</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>Taxane-refractory</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>41</SimplePara>
                        </entry>
                        <entry colname="c5">
                          <SimplePara>17</SimplePara>
                        </entry>
                        <entry colname="c6">
                          <SimplePara>4</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c1">
                          <SimplePara>Ixabepilone (20 mg/m<Superscript>2</Superscript> weekly for 3/4 weeks)</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>Wilding et al. [<CitationRef CitationID="CR109_16">109</CitationRef>]</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>Chemo-naïve</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>31</SimplePara>
                        </entry>
                        <entry colname="c5">
                          <SimplePara>32.3</SimplePara>
                        </entry>
                        <entry colname="c6">
                          <SimplePara>20.8</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c1">
                          <SimplePara>Ixabepilone (20 mg/m<Superscript>2</Superscript> weekly for 3/4 weeks)</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>Wilding et al. [<CitationRef CitationID="CR109_16">109</CitationRef>]</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>Taxane-refractory</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>36</SimplePara>
                        </entry>
                        <entry colname="c5">
                          <SimplePara>22.2</SimplePara>
                        </entry>
                        <entry colname="c6">
                          <SimplePara>7.1</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c1">
                          <SimplePara>Patupilone (10 mg/m<Superscript>2</Superscript> Q3 weeks)</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>Chi et al. [<CitationRef CitationID="CR110_16">110</CitationRef>]</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>Taxane-refractory</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>19</SimplePara>
                        </entry>
                        <entry colname="c5">
                          <SimplePara>42</SimplePara>
                        </entry>
                        <entry colname="c6">
                          <SimplePara>0</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c1">
                          <SimplePara>Patupilone (2.5 mg/m<Superscript>2</Superscript> weekly for 3/4 weeks)</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>Hussain et al. [<CitationRef CitationID="CR111_16">111</CitationRef>]</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>First-line or second-line</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>45</SimplePara>
                        </entry>
                        <entry colname="c5">
                          <SimplePara>13</SimplePara>
                        </entry>
                        <entry colname="c6">
                          <SimplePara>0</SimplePara>
                        </entry>
                      </row>
                    </tbody>
                  </tgroup>
                  <tfooter>
                    <SimplePara>Adapted with permission from Macmillan Publishers Ltd [97]. Copyright 2009</SimplePara>
                    <SimplePara>
                      <Emphasis Type="Italic">CRPC</Emphasis> castration-resistant prostate cancer, <Emphasis Type="Italic">ND</Emphasis> not determined, <Emphasis Type="Italic">PSA</Emphasis> prostate-specific antigen</SimplePara>
                  </tfooter>
                </Table>
              </Para>
              <Para TextBreak="No">Combination studies have been undertaken to determine if there is a synergistic clinical effect when ixabepilone is added to estramustine phosphate (EMP) therapy for the treatment of castration-resistant prostate cancer. Smaletz et al. [<CitationRef CitationID="CR112_16">112</CitationRef>] performed a dose-escalation study of BMS-247550 and determined that 35 mg/m<Superscript>2</Superscript> given over 3 h on day 1 of a 21-day cycle was the MTD when administered in combination with EMP (280 mg three times daily on days 1–5 of the 21-day cycle) for the treatment of chemotherapy-naïve patients with metastatic CRPC. Neutropenia was the dose-limiting toxicity that established the MTD. A subsequent multicenter, randomized noncomparative phase II trial [<CitationRef CitationID="CR107_16">107</CitationRef>] was undertaken to test the safety and clinical efficacy of ixabepilone (BMS-247550; 35 mg/m<Superscript>2</Superscript> every 3 weeks) with and without EMP (280 mg three times daily on days 1–5 of a 21-day cycle) in chemotherapy-naïve patients with metastatic CRPC. The primary endpoint was the proportion of patients achieving a ≥50% posttherapy reduction in PSA [<CitationRef CitationID="CR107_16">107</CitationRef>]. Forty-five patients were randomized to receive ixabepilone alone and 47 patients received the combination. Posttherapy PSA declines of at least 50% occurred more frequently in the combination group than in the monotherapy group; 31 of 45 patients (69%; 95% CI, 55–82%) in the combination cohort compared to 21 of 44 patients (48%; 95% CI, 33–64%) in the ixabepilone only group [<CitationRef CitationID="CR107_16">107</CitationRef>]. In patients with measurable disease, the objective response rate as assessed by RECIST criteria was also higher in the combination group than in the monotherapy group. Partial responses were observed in 11 of 23 (48%; 95% CI, 27–68%) patients in the combination cohort compared to 8 of 25 patients (32%; 95% CI, 14–50%) in the monotherapy group [<CitationRef CitationID="CR107_16">107</CitationRef>]. The most common toxic effects were neutropenia and neuropathy; treatment was discontinued due to neuropathy in eight patients (18%) in the combination cohort compared to 13 patients (28%) in the monotherapy group [<CitationRef CitationID="CR107_16">107</CitationRef>].</Para>
              <Para TextBreak="No">Rosenberg et al. [<CitationRef CitationID="CR108_16">108</CitationRef>] performed a multicenter, noncomparative, crossover phase II trial in which patients with castrate-resistant, taxane-refractory metastatic prostate cancer were randomized to receive either ixabepilone (35 mg/m<Superscript>2</Superscript> once every 3 weeks) or mitoxantrone (14 mg/m<Superscript>2</Superscript> once every 3 weeks plus daily oral prednisone). The primary objective was to determine if a ≥50% reduction in serum PSA would occur in at least 25% of these highly pretreated patients. Forty-one patients were accrued to each arm of the study. PSA declines of ≥50% were observed in 17% of ixabepilone-treated patients (95% CI, 7–32) and in 20% of mitoxantrone/prednisone treated patients (95% CI, 9–35) [<CitationRef CitationID="CR108_16">108</CitationRef>]. In those patients with evaluable measurable disease, partial responses were observed in 1 of 24 ixabepilone-treated and 2 of 21 mitoxantrone/prednisone-treated patients. Median overall survival was 10.4 months for those receiving ixabepilone and 9.8 months with mitoxantrone [<CitationRef CitationID="CR108_16">108</CitationRef>]. Assessment of survival by treatment cohort is confounded by the fact that 16 of 41 patients (39%) on second-line ixabepilone crossed over to MP treatment and 30 of 41 patients (73%) on second-line mitoxantrone/prednisone crossed over to ixabepilone therapy. The most common grade three and four toxicity associated with second-line treatment was neutropenia (54% in the ixabepilone cohort and 63% in the mitoxantrone cohort) [<CitationRef CitationID="CR108_16">108</CitationRef>]. These results indicate that single-agent ixabepilone has modest activity as second line chemotherapy in this population of taxane-refractory CRPC patients [<CitationRef CitationID="CR93_16">93</CitationRef>].</Para>
              <Para TextBreak="No">Wilding et al. [<CitationRef CitationID="CR109_16">109</CitationRef>] have published in abstract form updated results of a phase II trial examining the toxicity and antitumor activity of ixabepilone when administered on a weekly basis to both chemotherapy-naïve and taxane-refractory patients with castration-resistant prostate cancer. Ixabepilone was administered at a dose of 20 mg/m<Superscript>2</Superscript> weekly for three out of a total 4 week cycle. Patients were stratified to one of three arms, either chemotherapy-naïve, prior taxane-only treatment or a third arm which had received two prior chemotherapy regimens. The primary objective was a ≥50% reduction in serum PSA by Consensus Criteria in at least 50% of the chemotherapy-naïve patients and in at least 30% of the patients in each of the other two cohorts [<CitationRef CitationID="CR109_16">109</CitationRef>]. Rates of PSA response were higher in the chemotherapy-naïve group (10 of 31 patients, 32.3%) than in the group who had received prior taxane-only therapy (8 of 36 patients, 22.2%) [<CitationRef CitationID="CR109_16">109</CitationRef>]. For those patients with measurable disease, 20.8% in the chemotherapy-naïve group and 7.1% in the taxane-only group had evidence of partial objective responses by RECIST criteria [<CitationRef CitationID="CR109_16">109</CitationRef>]. The most common toxicities seen were neutropenia, sensory neuropathy, and fatigue. The toxicity profile for the weekly administration of ixabepilone compared favorably to the every-3-week schedule, with a decreased rate of myelosuppression in those patients who were chemotherapy-naïve.</Para>
              <Para TextBreak="No">Epothilone B (patupilone) has been evaluated in two separate phase II trials. Chi et al. published results in abstract form [<CitationRef CitationID="CR110_16">110</CitationRef>] of a phase II trial of patupilone (10 mg/m<Superscript>2</Superscript> IV every 3 weeks) for taxane-refractory, metastatic CRPC. PSA reduction of at least 50% was the primary endpoint with progression-free and overall survival, along with measurable disease response as secondary endpoints. At the time of abstract publication, 19 of 33 enrolled patients had data available and 8/19 patients (42%) had a reduction in serum PSA of at least 50%. No patients with measurable disease at that time had an objective response by RECIST criteria [<CitationRef CitationID="CR110_16">110</CitationRef>]. The most common grade 3 or 4 adverse events were diarrhea and fatigue with no hematologic adverse events [<CitationRef CitationID="CR110_16">110</CitationRef>].</Para>
              <Para TextBreak="No">Hussain et al. [<CitationRef CitationID="CR111_16">111</CitationRef>] report on a single arm phase II trial, the purpose of which was to establish the safety and efficacy of this agent in patients with castration-resistant prostate cancer. Forty-five patients with CRPC (median age 69 years; documented metastatic disease not required) were administered patupilone at a dose of 2.5 mg/m<Superscript>2</Superscript> weekly for 3 weeks of a 4-week cycle. 64% of patients had prior chemotherapy (55% having received previous taxane therapy). Six of 45 patients (13%) had a ≥50% decline in PSA; three of these patients had received prior taxane therapy. No patient with measurable disease had an objective response by RECIST criteria. Median overall survival was 13.4 months. The most common adverse events were grade 3 diarrhea and fatigue with no patients experiencing neutropenia or thrombocytopenia [<CitationRef CitationID="CR111_16">111</CitationRef>].</Para>
              <Para TextBreak="No">Beer et al. [<CitationRef CitationID="CR113_16">113</CitationRef>] have reported results of a phase II study evaluating the potential role of KOS-862 (epothilone D) in patients with docetaxel-refractory, castration-resistant prostate cancer. Epothilone D was administered at a dose of 100 mg/m<Superscript>2</Superscript> weekly for three out of a 4 week cycle. Because of excess toxicity and limited clinical efficacy of KOS-862, further investigational studies are not planned [<CitationRef CitationID="CR95_16">95</CitationRef>].</Para>
              <Para TextBreak="No">Phase II trials of the epothilones patupilone and ixabepilone for the treatment of patients with CRPC have demonstrated single-agent antitumor activity as well as incomplete cross-resistance with the taxanes [<CitationRef CitationID="CR94_16">94</CitationRef>]. Phase III trials are now needed to confirm the activity of the epothilones and better define their role in the treatment algorithm for castration-resistant prostate cancer [<CitationRef CitationID="CR93_16">93</CitationRef>].</Para>
            </Section2>
          </Section1>
          <Section1 ID="Sec18">
            <Heading>Cabazitaxel, a Novel Taxane for the Treatment of Advanced CRPC</Heading>
            <Para TextBreak="No">Cabazitaxel is a semisynthetic novel taxoid compound [<CitationRef CitationID="CR114_16">114</CitationRef>]. Preclinical in vitro studies have shown that cabazitaxel not only promotes tubulin polymerization and stabilizes microtubules as potently as docetaxel, but it also demonstrates greater cytotoxicity than docetaxel in a broad array of cancer cell lines with P-glycoprotein overexpression. Cabazitaxel displays decreased affinity for the P-glycoprotein 1 drug efflux pump. Additional preclinical studies with cabazitaxel have shown antitumor activity in mice bearing human DU-145 prostatic adenocarcinoma xenografts [<CitationRef CitationID="CR114_16">114</CitationRef>].</Para>
            <Para TextBreak="No">Phase I and II trials demonstrated antitumor activity in solid tumors including docetaxel-refractory mCRPC and that neutropenia was the primary dose-limiting toxicity [<CitationRef CitationID="CR115_16">115, 116</CitationRef>]. In June 2010, cabazitaxel (Jevtana, XRP6258) received US Food and Drug Administration approval for second-line use in combination with prednisone for the treatment of patients with metastatic CRPC previously treated with a docetaxel-containing treatment regimen. It was reviewed under the agency’s priority review program, an expedited 6-month review for drugs that offer an advance in treatment or provide a treatment where none exists. The approval was based on data from the international Phase III TROPIC trial conducted in 755 patients with mCRPC who all had been previously treated with docetaxel [117]. They were randomized to receive either cabazitaxel (25 mg/m<Superscript>2</Superscript>) or mitoxantrone (12 mg/m<Superscript>2</Superscript>), both administered intravenously every three weeks in combination with prednisone (CP vs. MP). The median overall survival was 15.1 months with cabazitaxel and 12.7 months with mitoxantrone (HR= 0.70; 95% CI, 0.59-0.83; p&lt; 0.0001). Investigator-assessed tumor response rates using RECIST criteria were 14.4% for CP vs 4.4% for MP (p= 0.0005), although no complete responses were observed on either treatment arm. The most common (≥5%) grade 3/4 adverse reactions were neutropenia, leukopenia, anemia, febrile neutropenia, diarrhea, fatigue and asthenia. The most common fatal adverse reactions in cabazitaxel-treated patients were infections and renal failure. The most frequent grade 3/4 toxicity was neutropenia (CP= 81.7%; MP=58.0%) and rates of febrile neutropenia were 7.5% and 1.3%, respectively. Granulocyte colony-stimulating factor (G-CSF) may be administered to reduce the risks of neutropenic complications associated with cabazitaxel use and primary prophylaxis with G-CSF should be considered in patients with high-risk clinical features.
With the approval of cabazitaxel, there is now a new treatment option for patients with the most advanced stage of prostate cancer and for whom there have been few options available. Cabazitaxel in combination with prednisone is the first and only FDA approved regimen to provide significant survival benefit in patients previously treated with a docetaxel-based regimen.</Para>
          </Section1>
          <Section1 ID="Sec19" Type="Conclusion">
            <Heading>Conclusion</Heading>
            <Para TextBreak="No">Microtubules are polymers composed of α,β-tubulin heterodimers. These filamentous structures associate to form the cytoskeleton of all eukaryotic cells. They also play critical roles in normal cellular physiology such as mitosis. There is a dynamic interplay between the intracellular pool of tubulin, and the mature microtubule. Many chemotherapeutic agents have been developed that shift the balance of this dynamic relationship in favor of either soluble or polymerized tubulin and these microtubule-targeting agents play a critical role in many different types of malignancies, including castration-resistant prostate cancer.</Para>
          </Section1>
        </Body>
        <BodyRef FileRef="BodyRef/PDF/978-1-60327-829-4_Chapter_16.pdf" OutputMedium="Online" PDFType="Typeset" TargetType="OnlinePDF"/>
        <ChapterBackmatter>
          <Bibliography ID="Bib1">
            <Heading>References</Heading>
            <Citation ID="CR1_16">
              <CitationNumber>1</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Hamel</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DG</Initials>
                  <FamilyName>Covell</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">Antimitotic peptides and depsipeptides</ArticleTitle>
                <JournalTitle>Curr Med Chem Anticancer Agents</JournalTitle>
                <VolumeID>2</VolumeID>
                <FirstPage>19</FirstPage>
                <LastPage>53</LastPage>
                <Occurrence Type="PID">
                  <Handle>12678750</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XislGmurk%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Hamel E, Covell DG. Antimitotic peptides and depsipeptides. Curr Med Chem Anticancer Agents 2002;2:19–53.</BibUnstructured>
            </Citation>
            <Citation ID="CR2_16">
              <CitationNumber>2</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MA</Initials>
                  <FamilyName>Jordan</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">Mechanism of action of antitumor drugs that interact with microtubules and tubulin</ArticleTitle>
                <JournalTitle>Curr Med Chem Anticancer Agents</JournalTitle>
                <VolumeID>2</VolumeID>
                <FirstPage>1</FirstPage>
                <LastPage>17</LastPage>
                <Occurrence Type="PID">
                  <Handle>12678749</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XislGmurg%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Jordan MA. Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr Med Chem Anticancer Agents 2002;2:1–17.</BibUnstructured>
            </Citation>
            <Citation ID="CR3_16">
              <CitationNumber>3</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MA</Initials>
                  <FamilyName>Jordan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Wilson</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Microtubules as a target for anticancer drugs</ArticleTitle>
                <JournalTitle>Nat Rev Cancer</JournalTitle>
                <VolumeID>4</VolumeID>
                <FirstPage>253</FirstPage>
                <LastPage>65</LastPage>
                <Occurrence Type="PID">
                  <Handle>15057285</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXis1Gmt74%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004;4:253–65.</BibUnstructured>
            </Citation>
            <Citation ID="CR4_16">
              <CitationNumber>4</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Jimenez-Barbero</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Amat-Guerri</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JP</Initials>
                  <FamilyName>Snyder</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">The solid state, solution and tubulin-bound conformations of agents that promote microtubule stabilization</ArticleTitle>
                <JournalTitle>Curr Med Chem Anticancer Agents</JournalTitle>
                <VolumeID>2</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>91</FirstPage>
                <LastPage>122</LastPage>
                <Occurrence Type="PID">
                  <Handle>12678753</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XislGmu74%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Jimenez-Barbero J, Amat-Guerri F, Snyder JP. The solid state, solution and tubulin-bound conformations of agents that promote microtubule stabilization. Curr Med Chem Anticancer Agents 2002;2(1):91–122.</BibUnstructured>
            </Citation>
            <Citation ID="CR5_16">
              <CitationNumber>5</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Desai</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TJ</Initials>
                  <FamilyName>Mitchison</FamilyName>
                </BibAuthorName>
                <Year>1997</Year>
                <ArticleTitle Language="En">Microtubule polymerization dynamics</ArticleTitle>
                <JournalTitle>Annu Rev Cell Dev Biol</JournalTitle>
                <VolumeID>13</VolumeID>
                <FirstPage>83</FirstPage>
                <LastPage>117</LastPage>
                <Occurrence Type="PID">
                  <Handle>9442869</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1cXisFSksg%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Desai A, Mitchison TJ. Microtubule polymerization dynamics. Annu Rev Cell Dev Biol 1997;13:83–117.</BibUnstructured>
            </Citation>
            <Citation ID="CR6_16">
              <CitationNumber>6</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>BR</Initials>
                  <FamilyName>Oakley</FamilyName>
                </BibAuthorName>
                <Year>2000</Year>
                <ArticleTitle Language="En">An abundance of tubulins</ArticleTitle>
                <JournalTitle>Trends Cell Biol</JournalTitle>
                <VolumeID>10</VolumeID>
                <FirstPage>537</FirstPage>
                <LastPage>42</LastPage>
                <Occurrence Type="PID">
                  <Handle>11121746</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXot12ltLs%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Oakley BR. An abundance of tubulins. Trends Cell Biol 2000;10:537–42.</BibUnstructured>
            </Citation>
            <Citation ID="CR7_16">
              <CitationNumber>7</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DJ</Initials>
                  <FamilyName>Sharp</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GC</Initials>
                  <FamilyName>Rogers</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JM</Initials>
                  <FamilyName>Scholey</FamilyName>
                </BibAuthorName>
                <Year>2000</Year>
                <ArticleTitle Language="En">Microtubule motors in mitosis</ArticleTitle>
                <JournalTitle>Nature</JournalTitle>
                <VolumeID>407</VolumeID>
                <FirstPage>41</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>10993066</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXmslSiu7s%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Sharp DJ, Rogers GC, Scholey JM. Microtubule motors in mitosis. Nature 2000;407:41–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR8_16">
              <CitationNumber>8</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>PM</Initials>
                  <FamilyName>Calvert</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>V</Initials>
                  <FamilyName>O’Neill</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Twelves</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2001</Year>
                <ArticleTitle Language="En">A phase I clinical and pharmacokinetic study of EPO906 (Epothilone B), given every three weeks, in patients with advanced solid tumors</ArticleTitle>
                <JournalTitle>Proc Am Soc Clin Oncol</JournalTitle>
                <VolumeID>20</VolumeID>
                <FirstPage>A429</FirstPage>
              </BibArticle>
              <BibUnstructured>Calvert PM, O’Neill V, Twelves C, et al. A phase I clinical and pharmacokinetic study of EPO906 (Epothilone B), given every three weeks, in patients with advanced solid tumors. Proc Am Soc Clin Oncol 2001;20:A429.</BibUnstructured>
            </Citation>
            <Citation ID="CR9_16">
              <CitationNumber>9</CitationNumber>
              <BibChapter>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Wilson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MA</Initials>
                  <FamilyName>Jordan</FamilyName>
                </BibAuthorName>
                <Year>1994</Year>
                <ChapterTitle Language="En">Pharmacological probes of microtubule function</ChapterTitle>
                <BibEditorName>
                  <Initials>J</Initials>
                  <FamilyName>Hyams</FamilyName>
                </BibEditorName>
                <BibEditorName>
                  <Initials>C</Initials>
                  <FamilyName>Lloyd</FamilyName>
                </BibEditorName>
                <Eds/>
                <BookTitle>Microtubules</BookTitle>
                <PublisherName>Wiley</PublisherName>
                <PublisherLocation>New York</PublisherLocation>
                <FirstPage>59</FirstPage>
                <LastPage>84</LastPage>
              </BibChapter>
              <BibUnstructured>Wilson L, Jordan MA. Pharmacological probes of microtubule function. In: Hyams J, Lloyd C, editors. Microtubules. New York: Wiley; 1994. p. 59–84.</BibUnstructured>
            </Citation>
            <Citation ID="CR10_16">
              <CitationNumber>10</CitationNumber>
              <BibBook>
                <BibAuthorName>
                  <Initials>MA</Initials>
                  <FamilyName>Jordan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Wilson</FamilyName>
                </BibAuthorName>
                <Year>1998</Year>
                <BookTitle>The use of drugs to study the role of microtubule assembly dynamics in living cells</BookTitle>
                <SeriesTitle Language="En">Molecular motors and the cytoskeleton. Methods Enzymol</SeriesTitle>
                <NumberInSeries>298</NumberInSeries>
                <FirstPage>252</FirstPage>
                <LastPage>76</LastPage>
              </BibBook>
              <BibUnstructured>Jordan MA, Wilson L. The use of drugs to study the role of microtubule assembly dynamics in living cells, Molecular motors and the cytoskeleton. Methods Enzymol, vol. 298. 1998. p. 252–76.</BibUnstructured>
            </Citation>
            <Citation ID="CR11_16">
              <CitationNumber>11</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Lobert</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Correia</FamilyName>
                </BibAuthorName>
                <Year>2000</Year>
                <ArticleTitle Language="En">Energetics of vinca alkaloid interactions with tubulin</ArticleTitle>
                <JournalTitle>Methods Enzymol</JournalTitle>
                <VolumeID>323</VolumeID>
                <FirstPage>77</FirstPage>
                <LastPage>103</LastPage>
                <Occurrence Type="PID">
                  <Handle>10944748</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXmsVGhsrw%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Lobert S, Correia J. Energetics of vinca alkaloid interactions with tubulin. Methods Enzymol 2000;323:77–103.</BibUnstructured>
            </Citation>
            <Citation ID="CR12_16">
              <CitationNumber>12</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>RB</Initials>
                  <FamilyName>Bai</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GR</Initials>
                  <FamilyName>Pettit</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Hamel</FamilyName>
                </BibAuthorName>
                <Year>1990</Year>
                <ArticleTitle Language="En">Dolastatin 10. a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain</ArticleTitle>
                <JournalTitle>Biochem Pharmacol</JournalTitle>
                <VolumeID>39</VolumeID>
                <FirstPage>1941</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>2353935</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK3cXkslSrt7Y%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Bai RB, Pettit GR, Hamel E. Dolastatin 10. a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain. Biochem Pharmacol 1990;39:1941–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR13_16">
              <CitationNumber>13</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>RB</Initials>
                  <FamilyName>Bai</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GR</Initials>
                  <FamilyName>Pettit</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Hamel</FamilyName>
                </BibAuthorName>
                <Year>1990</Year>
                <ArticleTitle Language="En">Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites</ArticleTitle>
                <JournalTitle>J Biol Chem</JournalTitle>
                <VolumeID>265</VolumeID>
                <FirstPage>17141</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>2211617</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK3cXmt1Chsb8%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Bai RB, Pettit GR, Hamel E. Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites. J Biol Chem 1990;265:17141–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR14_16">
              <CitationNumber>14</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Wilson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MA</Initials>
                  <FamilyName>Jordan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Morse</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RL</Initials>
                  <FamilyName>Margolis</FamilyName>
                </BibAuthorName>
                <Year>1982</Year>
                <ArticleTitle Language="En">Interaction of vinblastine with steady-state microtubules in vitro</ArticleTitle>
                <JournalTitle>J Mol Biol</JournalTitle>
                <VolumeID>159</VolumeID>
                <FirstPage>129</FirstPage>
                <LastPage>49</LastPage>
              </BibArticle>
              <BibUnstructured>Wilson L, Jordan MA, Morse A, Margolis RL. Interaction of vinblastine with steady-state microtubules in vitro. J Mol Biol 1982;159:129–49.</BibUnstructured>
            </Citation>
            <Citation ID="CR15_16">
              <CitationNumber>15</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JJ</Initials>
                  <FamilyName>Correia</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Lobert</FamilyName>
                </BibAuthorName>
                <Year>2001</Year>
                <ArticleTitle Language="En">Physiochemical aspects of tubulin-interacting antimitotic drugs</ArticleTitle>
                <JournalTitle>Curr Pharm Des</JournalTitle>
                <VolumeID>7</VolumeID>
                <IssueID>13</IssueID>
                <FirstPage>1213</FirstPage>
                <LastPage>28</LastPage>
                <Occurrence Type="PID">
                  <Handle>11472263</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXmt1enu7c%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Correia JJ, Lobert S. Physiochemical aspects of tubulin-interacting antimitotic drugs. Curr Pharm Des 2001;7(13):1213–28.</BibUnstructured>
            </Citation>
            <Citation ID="CR16_16">
              <CitationNumber>16</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>GC</Initials>
                  <FamilyName>Na</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SN</Initials>
                  <FamilyName>Timasheff</FamilyName>
                </BibAuthorName>
                <Year>1980</Year>
                <ArticleTitle Language="En">Thermodynamic linkage between tubulin self-association and the binding of vinblastine</ArticleTitle>
                <JournalTitle>Biochemistry</JournalTitle>
                <VolumeID>19</VolumeID>
                <IssueID>7</IssueID>
                <FirstPage>1347</FirstPage>
                <LastPage>54</LastPage>
                <Occurrence Type="PID">
                  <Handle>7387993</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaL3cXhsFOqs78%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Na GC, Timasheff SN. Thermodynamic linkage between tubulin self-association and the binding of vinblastine. Biochemistry 1980;19(7):1347–54.</BibUnstructured>
            </Citation>
            <Citation ID="CR17_16">
              <CitationNumber>17</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MA</Initials>
                  <FamilyName>Jordan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RL</Initials>
                  <FamilyName>Margolis</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RH</Initials>
                  <FamilyName>Himes</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Wilson</FamilyName>
                </BibAuthorName>
                <Year>1986</Year>
                <ArticleTitle Language="En">Identification of a distinct class of vinblastine binding sites on microtubules</ArticleTitle>
                <JournalTitle>J Mol Biol</JournalTitle>
                <VolumeID>187</VolumeID>
                <FirstPage>61</FirstPage>
                <LastPage>73</LastPage>
                <Occurrence Type="PID">
                  <Handle>3959083</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaL28Xht1aksbY%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Jordan MA, Margolis RL, Himes RH, Wilson L. Identification of a distinct class of vinblastine binding sites on microtubules. J Mol Biol 1986;187:61–73.</BibUnstructured>
            </Citation>
            <Citation ID="CR18_16">
              <CitationNumber>18</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>WD</Initials>
                  <FamilyName>Singer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MA</Initials>
                  <FamilyName>Jordan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Wilson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RH</Initials>
                  <FamilyName>Himes</FamilyName>
                </BibAuthorName>
                <Year>1989</Year>
                <ArticleTitle Language="En">Binding of vinblastine to stabilized microtubules</ArticleTitle>
                <JournalTitle>Mol Pharmacol</JournalTitle>
                <VolumeID>36</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>366</FirstPage>
                <LastPage>70</LastPage>
                <Occurrence Type="PID">
                  <Handle>2571072</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaL1MXmtVyrs70%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Singer WD, Jordan MA, Wilson L, Himes RH. Binding of vinblastine to stabilized microtubules. Mol Pharmacol 1989;36(3):366–70.</BibUnstructured>
            </Citation>
            <Citation ID="CR19_16">
              <CitationNumber>19</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Panda</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MA</Initials>
                  <FamilyName>Jordan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Chin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Wilson</FamilyName>
                </BibAuthorName>
                <Year>1996</Year>
                <ArticleTitle Language="En">Differential effects of vinblastine on polymerization and dynamics at opposite microtubule ends</ArticleTitle>
                <JournalTitle>J Biol Chem</JournalTitle>
                <VolumeID>271</VolumeID>
                <FirstPage>29807</FirstPage>
                <LastPage>12</LastPage>
                <Occurrence Type="PID">
                  <Handle>8939919</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK28XntFKktrw%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Panda D, Jordan MA, Chin K, Wilson L. Differential effects of vinblastine on polymerization and dynamics at opposite microtubule ends. J Biol Chem 1996;271:29807–12.</BibUnstructured>
            </Citation>
            <Citation ID="CR20_16">
              <CitationNumber>20</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Panda</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Miller</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Wilson</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">Determination of the size and chemical nature of the stabilizing cap at microtubule ends using modulators of polymerization dynamics</ArticleTitle>
                <JournalTitle>Biochemistry</JournalTitle>
                <VolumeID>41</VolumeID>
                <FirstPage>1609</FirstPage>
                <LastPage>17</LastPage>
                <Occurrence Type="PID">
                  <Handle>11814355</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38Xis1yjtw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Panda D, Miller H, Wilson L. Determination of the size and chemical nature of the stabilizing cap at microtubule ends using modulators of polymerization dynamics. Biochemistry 2002;41:1609–17.</BibUnstructured>
            </Citation>
            <Citation ID="CR21_16">
              <CitationNumber>21</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>SB</Initials>
                  <FamilyName>Hastie</FamilyName>
                </BibAuthorName>
                <Year>1991</Year>
                <ArticleTitle Language="En">Interactions of colchicine with tubulin</ArticleTitle>
                <JournalTitle>Pharmacol Ther</JournalTitle>
                <VolumeID>512</VolumeID>
                <FirstPage>377</FirstPage>
                <LastPage>401</LastPage>
              </BibArticle>
              <BibUnstructured>Hastie SB. Interactions of colchicine with tubulin. Pharmacol Ther 1991;512:377–401.</BibUnstructured>
            </Citation>
            <Citation ID="CR22_16">
              <CitationNumber>22</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Sternlicht</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>I</Initials>
                  <FamilyName>Ringel</FamilyName>
                </BibAuthorName>
                <Year>1979</Year>
                <ArticleTitle Language="En">Colchicine inhibition of microtubule assembly via copolymer formations</ArticleTitle>
                <JournalTitle>J Biol Chem</JournalTitle>
                <VolumeID>254</VolumeID>
                <FirstPage>10540</FirstPage>
                <LastPage>50</LastPage>
                <Occurrence Type="PID">
                  <Handle>489611</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaE1MXlslSgs70%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Sternlicht H, Ringel I. Colchicine inhibition of microtubule assembly via copolymer formations. J Biol Chem 1979;254:10540–50.</BibUnstructured>
            </Citation>
            <Citation ID="CR23_16">
              <CitationNumber>23</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Sternlicht</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>I</Initials>
                  <FamilyName>Ringel</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Szasz</FamilyName>
                </BibAuthorName>
                <Year>1983</Year>
                <ArticleTitle Language="En">Theory for modelling the copolymerization of tubulin and tubulin-colchicine complex</ArticleTitle>
                <JournalTitle>Biophys J</JournalTitle>
                <VolumeID>42</VolumeID>
                <FirstPage>255</FirstPage>
                <LastPage>67</LastPage>
                <Occurrence Type="PID">
                  <Handle>6871371</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaL3sXktVajsLw%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Sternlicht H, Ringel I, Szasz J. Theory for modelling the copolymerization of tubulin and tubulin-colchicine complex. Biophys J 1983;42:255–67.</BibUnstructured>
            </Citation>
            <Citation ID="CR24_16">
              <CitationNumber>24</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>KW</Initials>
                  <FamilyName>Farrell</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Wilson</FamilyName>
                </BibAuthorName>
                <Year>1984</Year>
                <ArticleTitle Language="En">The differential kinetic stabilization of opposite microtubule ends by tubulin–colchicine complexes</ArticleTitle>
                <JournalTitle>Biochemistry</JournalTitle>
                <VolumeID>23</VolumeID>
                <FirstPage>3741</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>6477893</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaL2cXksFShs7Y%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Farrell KW, Wilson L. The differential kinetic stabilization of opposite microtubule ends by tubulin–colchicine complexes. Biochemistry 1984;23:3741–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR25_16">
              <CitationNumber>25</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Skoufias</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Wilson</FamilyName>
                </BibAuthorName>
                <Year>1992</Year>
                <ArticleTitle Language="En">Mechanism of inhibition of microtubule polymerization by colchicine: inhibitory potencies of unliganded colchicine and tubulin–colchicine complexes</ArticleTitle>
                <JournalTitle>Biochemistry</JournalTitle>
                <VolumeID>31</VolumeID>
                <FirstPage>738</FirstPage>
                <LastPage>46</LastPage>
                <Occurrence Type="PID">
                  <Handle>1731931</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK38Xltlyjsw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Skoufias D, Wilson L. Mechanism of inhibition of microtubule polymerization by colchicine: inhibitory potencies of unliganded colchicine and tubulin–colchicine complexes. Biochemistry 1992;31:738–46.</BibUnstructured>
            </Citation>
            <Citation ID="CR26_16">
              <CitationNumber>26</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>RL</Initials>
                  <FamilyName>Margolis</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CT</Initials>
                  <FamilyName>Rauch</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Wilson</FamilyName>
                </BibAuthorName>
                <Year>1980</Year>
                <ArticleTitle Language="En">Mechanism of colchicine dimer addition to microtubule ends: implications for the microtubule polymerization mechanism</ArticleTitle>
                <JournalTitle>Biochemistry</JournalTitle>
                <VolumeID>19</VolumeID>
                <FirstPage>5550</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>7459331</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaL3cXmtFKrt78%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Margolis RL, Rauch CT, Wilson L. Mechanism of colchicine dimer addition to microtubule ends: implications for the microtubule polymerization mechanism. Biochemistry 1980;19:5550–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR27_16">
              <CitationNumber>27</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Wilson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KW</Initials>
                  <FamilyName>Farrell</FamilyName>
                </BibAuthorName>
                <Year>1986</Year>
                <ArticleTitle Language="En">Kinetics and steady-state dynamics of tubulin addition and loss at opposite microtubule ends: the mechanism of action of colchicine</ArticleTitle>
                <JournalTitle>Ann N Y Acad Sci</JournalTitle>
                <VolumeID>466</VolumeID>
                <FirstPage>690</FirstPage>
                <LastPage>708</LastPage>
                <Occurrence Type="PID">
                  <Handle>3460444</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaL28XlvVGqu7Y%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Wilson L, Farrell KW. Kinetics and steady-state dynamics of tubulin addition and loss at opposite microtubule ends: the mechanism of action of colchicine. Ann N Y Acad Sci 1986;466:690–708.</BibUnstructured>
            </Citation>
            <Citation ID="CR28_16">
              <CitationNumber>28</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Panda</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>BL</Initials>
                  <FamilyName>Goode</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SC</Initials>
                  <FamilyName>Feinstein</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Wilson</FamilyName>
                </BibAuthorName>
                <Year>1995</Year>
                <ArticleTitle Language="En">Kinetic stabilization of microtubule dynamics at steady state by tau and microtubule-binding domains of tau</ArticleTitle>
                <JournalTitle>Biochemistry</JournalTitle>
                <VolumeID>34</VolumeID>
                <FirstPage>11117</FirstPage>
                <LastPage>27</LastPage>
                <Occurrence Type="PID">
                  <Handle>7669769</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2MXnsVKqtbo%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Panda D, Goode BL, Feinstein SC, Wilson L. Kinetic stabilization of microtubule dynamics at steady state by tau and microtubule-binding domains of tau. Biochemistry 1995;34:11117–27.</BibUnstructured>
            </Citation>
            <Citation ID="CR29_16">
              <CitationNumber>29</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Jordan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JA</Initials>
                  <FamilyName>Hadfield</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>NJ</Initials>
                  <FamilyName>Lawrence</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1998</Year>
                <ArticleTitle Language="En">Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle</ArticleTitle>
                <JournalTitle>Med Res Rev</JournalTitle>
                <VolumeID>18</VolumeID>
                <FirstPage>259</FirstPage>
                <LastPage>96</LastPage>
                <Occurrence Type="PID">
                  <Handle>9664292</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1cXkvVeisLY%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Jordan A, Hadfield JA, Lawrence NJ, et al. Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle. Med Res Rev 1998;18:259–96.</BibUnstructured>
            </Citation>
            <Citation ID="CR30_16">
              <CitationNumber>30</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>GR</Initials>
                  <FamilyName>Pettit</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GM</Initials>
                  <FamilyName>Cragg</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SB</Initials>
                  <FamilyName>Singh</FamilyName>
                </BibAuthorName>
                <Year>1987</Year>
                <ArticleTitle Language="En">Antineoplastic agents, 122. Constituents of<Emphasis Type="Italic">Combretum caffrum</Emphasis>
                </ArticleTitle>
                <JournalTitle>J Nat Prod</JournalTitle>
                <VolumeID>50</VolumeID>
                <FirstPage>386</FirstPage>
                <LastPage>91</LastPage>
                <Occurrence Type="PID">
                  <Handle>3668557</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaL1cXnt1SgtQ%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Pettit GR, Cragg GM, Singh SB. Antineoplastic agents, 122. Constituents of<Emphasis Type="Italic">Combretum caffrum</Emphasis>. J Nat Prod 1987;50:386–91.</BibUnstructured>
            </Citation>
            <Citation ID="CR31_16">
              <CitationNumber>31</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>GM</Initials>
                  <FamilyName>Tozer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Kanthou</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CS</Initials>
                  <FamilyName>Parkins</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2002</Year>
                <ArticleTitle Language="En">The biology of the combretastatins as tumour vascular targeting agents</ArticleTitle>
                <JournalTitle>Int J Exp Pathol</JournalTitle>
                <VolumeID>83</VolumeID>
                <FirstPage>21</FirstPage>
                <LastPage>38</LastPage>
                <Occurrence Type="PID">
                  <Handle>12059907</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38Xmt1WksLc%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Tozer GM, Kanthou C, Parkins CS, et al. The biology of the combretastatins as tumour vascular targeting agents. Int J Exp Pathol 2002;83:21–38.</BibUnstructured>
            </Citation>
            <Citation ID="CR32_16">
              <CitationNumber>32</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>GR</Initials>
                  <FamilyName>Pettit</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Temple</FamilyName>
                  <Suffix>Jr</Suffix>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>VL</Initials>
                  <FamilyName>Narayanan</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1995</Year>
                <ArticleTitle Language="En">Antineoplastic agents 322. Synthesis of combretastatin A-4 prodrugs</ArticleTitle>
                <JournalTitle>Anticancer Drug Des</JournalTitle>
                <VolumeID>10</VolumeID>
                <FirstPage>299</FirstPage>
                <LastPage>309</LastPage>
                <Occurrence Type="PID">
                  <Handle>7786396</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2MXms1Wktbs%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Pettit GR, Temple Jr C, Narayanan VL, et al. Antineoplastic agents 322. Synthesis of combretastatin A-4 prodrugs. Anticancer Drug Des 1995;10:299–309.</BibUnstructured>
            </Citation>
            <Citation ID="CR33_16">
              <CitationNumber>33</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>GG</Initials>
                  <FamilyName>Dark</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SA</Initials>
                  <FamilyName>Hill</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>VE</Initials>
                  <FamilyName>Prise</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1997</Year>
                <ArticleTitle Language="En">Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>57</VolumeID>
                <FirstPage>1829</FirstPage>
                <LastPage>34</LastPage>
                <Occurrence Type="PID">
                  <Handle>9157969</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2sXjtlGnsbk%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Dark GG, Hill SA, Prise VE, et al. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 1997;57:1829–34.</BibUnstructured>
            </Citation>
            <Citation ID="CR34_16">
              <CitationNumber>34</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Ahmed</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LI</Initials>
                  <FamilyName>Eijk</FamilyName>
                  <Particle>Van</Particle>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JC</Initials>
                  <FamilyName>Bouma-Ter Steege</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2003</Year>
                <ArticleTitle Language="En">Vascular targeting effect of combretastatin A-4 phosphate dominates the inherent angiogenesis inhibitory activity</ArticleTitle>
                <JournalTitle>Int J Cancer</JournalTitle>
                <VolumeID>105</VolumeID>
                <FirstPage>20</FirstPage>
                <LastPage>5</LastPage>
                <Occurrence Type="PID">
                  <Handle>12672025</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXjtVWrsr4%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Ahmed B, Van Eijk LI, Bouma-Ter Steege JC, et al. Vascular targeting effect of combretastatin A-4 phosphate dominates the inherent angiogenesis inhibitory activity. Int J Cancer 2003;105:20–5.</BibUnstructured>
            </Citation>
            <Citation ID="CR35_16">
              <CitationNumber>35</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Schumacher</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Neuhaus</FamilyName>
                </BibAuthorName>
                <Year>2001</Year>
                <ArticleTitle Language="En">The physiological estrogen metabolite 2-methoxyestradiol reduces tumor growth and induces apoptosis in human solid tumors</ArticleTitle>
                <JournalTitle>J Cancer Res Clin Oncol</JournalTitle>
                <VolumeID>127</VolumeID>
                <FirstPage>405</FirstPage>
                <LastPage>10</LastPage>
                <Occurrence Type="PID">
                  <Handle>11469676</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXktFWgsrg%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Schumacher G, Neuhaus P. The physiological estrogen metabolite 2-methoxyestradiol reduces tumor growth and induces apoptosis in human solid tumors. J Cancer Res Clin Oncol 2001;127:405–10.</BibUnstructured>
            </Citation>
            <Citation ID="CR36_16">
              <CitationNumber>36</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>RJ</Initials>
                  <FamilyName>D’Amato</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CM</Initials>
                  <FamilyName>Lin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Flynn</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1994</Year>
                <ArticleTitle Language="En">2-Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site</ArticleTitle>
                <JournalTitle>Proc Natl Acad Sci U S A</JournalTitle>
                <VolumeID>91</VolumeID>
                <FirstPage>3964</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>8171020</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>D’Amato RJ, Lin CM, Flynn E, et al. 2-Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site. Proc Natl Acad Sci U S A 1994;91:3964–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR37_16">
              <CitationNumber>37</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Fotsis</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Zhang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MS</Initials>
                  <FamilyName>Pepper</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1994</Year>
                <ArticleTitle Language="En">The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth</ArticleTitle>
                <JournalTitle>Nature</JournalTitle>
                <VolumeID>368</VolumeID>
                <FirstPage>237</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>7511798</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2cXitlKns7Y%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Fotsis T, Zhang Y, Pepper MS, et al. The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth. Nature 1994;368:237–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR38_16">
              <CitationNumber>38</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Ines</FamilyName>
                  <Particle>de</Particle>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Leynadier</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>I</Initials>
                  <FamilyName>Barasoain</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1994</Year>
                <ArticleTitle Language="En">Inhibition of microtubules and cell cycle arrest by a new 1-deaza-7, 8-dihydropteridine antitumor drug, CI 980, and by its chiral isomer, NSC 613863</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>54</VolumeID>
                <FirstPage>75</FirstPage>
                <LastPage>84</LastPage>
                <Occurrence Type="PID">
                  <Handle>8261466</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>de Ines C, Leynadier D, Barasoain I, et al. Inhibition of microtubules and cell cycle arrest by a new 1-deaza-7, 8-dihydropteridine antitumor drug, CI 980, and by its chiral isomer, NSC 613863. Cancer Res 1994;54:75–84.</BibUnstructured>
            </Citation>
            <Citation ID="CR39_16">
              <CitationNumber>39</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>WR</Initials>
                  <FamilyName>Waud</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WR</Initials>
                  <FamilyName>Leopold</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WL</Initials>
                  <FamilyName>Elliott</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1990</Year>
                <ArticleTitle Language="En">Antitumor activity of ethyl 5-amino-1,2-dihydro-2-methyl-3-phenyl-pyrido [3,4-b]pyrazin-7-ylcarbamate, 2-hydroxyethanesulfonate, hydrate (NSC 370147) against selected tumor systems in culture and in mice</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>50</VolumeID>
                <FirstPage>3239</FirstPage>
                <LastPage>44</LastPage>
                <Occurrence Type="PID">
                  <Handle>2334919</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK3cXltVyrsLw%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Waud WR, Leopold WR, Elliott WL, et al. Antitumor activity of ethyl 5-amino-1,2-dihydro-2-methyl-3-phenyl-pyrido [3,4-b]pyrazin-7-ylcarbamate, 2-hydroxyethanesulfonate, hydrate (NSC 370147) against selected tumor systems in culture and in mice. Cancer Res 1990;50:3239–44.</BibUnstructured>
            </Citation>
            <Citation ID="CR40_16">
              <CitationNumber>40</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Verdier-Pinard</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JA</Initials>
                  <FamilyName>Kepler</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GR</Initials>
                  <FamilyName>Pettit</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Hamel</FamilyName>
                </BibAuthorName>
                <Year>2000</Year>
                <ArticleTitle Language="En">Sustained intracellular retention of dolastatin 10 causes its potent antimitotic activity</ArticleTitle>
                <JournalTitle>Mol Pharmacol</JournalTitle>
                <VolumeID>57</VolumeID>
                <FirstPage>180</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>10617693</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXhslCkug%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Verdier-Pinard P, Kepler JA, Pettit GR, Hamel E. Sustained intracellular retention of dolastatin 10 causes its potent antimitotic activity. Mol Pharmacol 2000;57:180–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR41_16">
              <CitationNumber>41</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>WD</Initials>
                  <FamilyName>Singer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RT</Initials>
                  <FamilyName>Hersh</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RH</Initials>
                  <FamilyName>Himes</FamilyName>
                </BibAuthorName>
                <Year>1988</Year>
                <ArticleTitle Language="En">Effect of solution variables on the binding of vinblastine to tubulin</ArticleTitle>
                <JournalTitle>Biochem Pharmacol</JournalTitle>
                <VolumeID>37</VolumeID>
                <FirstPage>2691</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>3390227</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaL1cXkvVGrur0%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Singer WD, Hersh RT, Himes RH. Effect of solution variables on the binding of vinblastine to tubulin. Biochem Pharmacol 1988;37:2691–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR42_16">
              <CitationNumber>42</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Bai</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GF</Initials>
                  <FamilyName>Taylor</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JM</Initials>
                  <FamilyName>Schmidt</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MD</Initials>
                  <FamilyName>Williams</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JA</Initials>
                  <FamilyName>Kepler</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GR</Initials>
                  <FamilyName>Pettit</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Hamel</FamilyName>
                </BibAuthorName>
                <Year>1995</Year>
                <ArticleTitle Language="En">Interaction of dolastatin 10 with tubulin: Induction of aggregation and binding and dissociation reactions</ArticleTitle>
                <JournalTitle>Mol Pharmacol</JournalTitle>
                <VolumeID>47</VolumeID>
                <FirstPage>965</FirstPage>
                <LastPage>76</LastPage>
                <Occurrence Type="PID">
                  <Handle>7746283</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2MXls12ktLk%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Bai R, Taylor GF, Schmidt JM, Williams MD, Kepler JA, Pettit GR, et al. Interaction of dolastatin 10 with tubulin: Induction of aggregation and binding and dissociation reactions. Mol Pharmacol 1995;47:965–76.</BibUnstructured>
            </Citation>
            <Citation ID="CR43_16">
              <CitationNumber>43</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AR</Initials>
                  <FamilyName>Safa</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Hamel</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RL</Initials>
                  <FamilyName>Felsted</FamilyName>
                </BibAuthorName>
                <Year>1987</Year>
                <ArticleTitle Language="En">Photoaffinity labeling of tubulin subunits with a photoactive analogue of vinblastine</ArticleTitle>
                <JournalTitle>Biochemistry</JournalTitle>
                <VolumeID>26</VolumeID>
                <FirstPage>97</FirstPage>
                <LastPage>102</LastPage>
                <Occurrence Type="PID">
                  <Handle>3828312</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaL2sXks1Ogug%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Safa AR, Hamel E, Felsted RL. Photoaffinity labeling of tubulin subunits with a photoactive analogue of vinblastine. Biochemistry 1987;26:97–102.</BibUnstructured>
            </Citation>
            <Citation ID="CR44_16">
              <CitationNumber>44</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>RL</Initials>
                  <FamilyName>Bai</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GR</Initials>
                  <FamilyName>Pettit</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Hamel</FamilyName>
                </BibAuthorName>
                <Year>1990</Year>
                <ArticleTitle Language="En">Structure-activity studies with chiral isomers and with segments of the antimitotic marine peptide dolastatin 10</ArticleTitle>
                <JournalTitle>Biochem Pharmacol</JournalTitle>
                <VolumeID>40</VolumeID>
                <FirstPage>1859</FirstPage>
                <LastPage>64</LastPage>
                <Occurrence Type="PID">
                  <Handle>2242019</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK3MXpsVKhsA%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Bai RL, Pettit GR, Hamel E. Structure-activity studies with chiral isomers and with segments of the antimitotic marine peptide dolastatin 10. Biochem Pharmacol 1990;40:1859–64.</BibUnstructured>
            </Citation>
            <Citation ID="CR45_16">
              <CitationNumber>45</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Bai</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MC</Initials>
                  <FamilyName>Roach</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SK</Initials>
                  <FamilyName>Jayaram</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1993</Year>
                <ArticleTitle Language="En">Differential effects of active isomers, segments, and analogs of dolastatin 10 on ligand interactions with tubulin. Correlation with cytotoxicity</ArticleTitle>
                <JournalTitle>Biochem Pharmacol</JournalTitle>
                <VolumeID>45</VolumeID>
                <FirstPage>1503</FirstPage>
                <LastPage>15</LastPage>
                <Occurrence Type="PID">
                  <Handle>8471072</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK3sXks1ansL8%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Bai R, Roach MC, Jayaram SK, et al. Differential effects of active isomers, segments, and analogs of dolastatin 10 on ligand interactions with tubulin. Correlation with cytotoxicity. Biochem Pharmacol 1993;45:1503–15.</BibUnstructured>
            </Citation>
            <Citation ID="CR46_16">
              <CitationNumber>46</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>GR</Initials>
                  <FamilyName>Pettit</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JK</Initials>
                  <FamilyName>Srirangam</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Barkoczy</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1995</Year>
                <ArticleTitle Language="En">Antineoplastic agents 337. Synthesis of dolastatin 10 structural modifications</ArticleTitle>
                <JournalTitle>Anticancer Drug Des</JournalTitle>
                <VolumeID>10</VolumeID>
                <FirstPage>529</FirstPage>
                <LastPage>44</LastPage>
                <Occurrence Type="PID">
                  <Handle>7495477</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2MXhtVSmurbL</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Pettit GR, Srirangam JK, Barkoczy J, et al. Antineoplastic agents 337. Synthesis of dolastatin 10 structural modifications. Anticancer Drug Des 1995;10:529–44.</BibUnstructured>
            </Citation>
            <Citation ID="CR47_16">
              <CitationNumber>47</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Li</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Kobayashi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Hashimoto</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1994</Year>
                <ArticleTitle Language="En">Interaction of marine toxin dolastatin 10 with porcine brain tubulin: competitive inhibition of rhizoxin and phomopsin A binding</ArticleTitle>
                <JournalTitle>Chem Biol Interact</JournalTitle>
                <VolumeID>93</VolumeID>
                <FirstPage>175</FirstPage>
                <LastPage>83</LastPage>
                <Occurrence Type="PID">
                  <Handle>7923438</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Li Y, Kobayashi H, Hashimoto Y, et al. Interaction of marine toxin dolastatin 10 with porcine brain tubulin: competitive inhibition of rhizoxin and phomopsin A binding. Chem Biol Interact 1994;93:175–83.</BibUnstructured>
            </Citation>
            <Citation ID="CR48_16">
              <CitationNumber>48</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Otani</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Natsume</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JI</Initials>
                  <FamilyName>Watanabe</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2000</Year>
                <ArticleTitle Language="En">TZT-1027, an antimicrotubule agent, attacks tumor vasculature and induces tumor cell death</ArticleTitle>
                <JournalTitle>Jpn J Cancer Res</JournalTitle>
                <VolumeID>91</VolumeID>
                <FirstPage>837</FirstPage>
                <LastPage>44</LastPage>
                <Occurrence Type="PID">
                  <Handle>10965026</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXmt1OhsL8%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Otani M, Natsume T, Watanabe JI, et al. TZT-1027, an antimicrotubule agent, attacks tumor vasculature and induces tumor cell death. Jpn J Cancer Res 2000;91:837–44.</BibUnstructured>
            </Citation>
            <Citation ID="CR49_16">
              <CitationNumber>49</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Natsume</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Watanabe</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Tamaoki</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2000</Year>
                <ArticleTitle Language="En">Characterization of the interaction of TZT-1027, a potent antitumor agent, with tubulin</ArticleTitle>
                <JournalTitle>Jpn J Cancer Res</JournalTitle>
                <VolumeID>91</VolumeID>
                <FirstPage>737</FirstPage>
                <LastPage>47</LastPage>
                <Occurrence Type="PID">
                  <Handle>10920282</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXmtFyntLg%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Natsume T, Watanabe J, Tamaoki S, et al. Characterization of the interaction of TZT-1027, a potent antitumor agent, with tubulin. Jpn J Cancer Res 2000;91:737–47.</BibUnstructured>
            </Citation>
            <Citation ID="CR50_16">
              <CitationNumber>50</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MC</Initials>
                  <FamilyName>Wani</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>HL</Initials>
                  <FamilyName>Taylor</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>ME</Initials>
                  <FamilyName>Wall</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Coggan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AT</Initials>
                  <FamilyName>McPhail</FamilyName>
                </BibAuthorName>
                <Year>1971</Year>
                <ArticleTitle Language="En">Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from<Emphasis Type="Italic">Taxus brevifolia</Emphasis>
                </ArticleTitle>
                <JournalTitle>J Am Chem Soc</JournalTitle>
                <VolumeID>93</VolumeID>
                <FirstPage>2325</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>5553076</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaE3MXktVKisLc%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Wani MC, Taylor HL, Wall ME, Coggan P, McPhail AT. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from<Emphasis Type="Italic">Taxus brevifolia</Emphasis>. J Am Chem Soc 1971;93:2325–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR51_16">
              <CitationNumber>51</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>PB</Initials>
                  <FamilyName>Schiff</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Fant</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SB</Initials>
                  <FamilyName>Horwitz</FamilyName>
                </BibAuthorName>
                <Year>1979</Year>
                <ArticleTitle Language="En">Promotion of microtubule assembly in vitro by taxol</ArticleTitle>
                <JournalTitle>Nature</JournalTitle>
                <VolumeID>277</VolumeID>
                <FirstPage>665</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>423966</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaE1MXkvVCitrY%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature 1979;277:665–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR52_16">
              <CitationNumber>52</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>PB</Initials>
                  <FamilyName>Schiff</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SB</Initials>
                  <FamilyName>Horwitz</FamilyName>
                </BibAuthorName>
                <Year>1980</Year>
                <ArticleTitle Language="En">Taxol stabilizes microtubules in mouse fibroblast cells</ArticleTitle>
                <JournalTitle>Proc Natl Acad Sci U S A</JournalTitle>
                <VolumeID>77</VolumeID>
                <FirstPage>1561</FirstPage>
                <LastPage>5</LastPage>
                <Occurrence Type="PID">
                  <Handle>6103535</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaL3cXktVSnt7g%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Schiff PB, Horwitz SB. Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci U S A 1980;77:1561–5.</BibUnstructured>
            </Citation>
            <Citation ID="CR53_16">
              <CitationNumber>53</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>PB</Initials>
                  <FamilyName>Schiff</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SB</Initials>
                  <FamilyName>Horwitz</FamilyName>
                </BibAuthorName>
                <Year>1981</Year>
                <ArticleTitle Language="En">Taxol assembles tubulin in the absence of exogenous guanosine 5′-triphosphate or microtubule-associated proteins</ArticleTitle>
                <JournalTitle>Biochemistry</JournalTitle>
                <VolumeID>20</VolumeID>
                <FirstPage>3247</FirstPage>
                <LastPage>52</LastPage>
                <Occurrence Type="PID">
                  <Handle>6113842</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaL3MXktFyjs78%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Schiff PB, Horwitz SB. Taxol assembles tubulin in the absence of exogenous guanosine 5′-triphosphate or microtubule-associated proteins. Biochemistry 1981;20:3247–52.</BibUnstructured>
            </Citation>
            <Citation ID="CR54_16">
              <CitationNumber>54</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JF</Initials>
                  <FamilyName>Diaz</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JM</Initials>
                  <FamilyName>Valpuesta</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Chacon</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Diakun</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JM</Initials>
                  <FamilyName>Andreu</FamilyName>
                </BibAuthorName>
                <Year>1998</Year>
                <ArticleTitle Language="En">Changes in microtubule protofilament number induced by Taxol binding to an easily accessible site. Internal microtubule dynamics</ArticleTitle>
                <JournalTitle>J Biol Chem</JournalTitle>
                <VolumeID>273</VolumeID>
                <FirstPage>33803</FirstPage>
                <LastPage>10</LastPage>
                <Occurrence Type="PID">
                  <Handle>9837970</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1MXjvVE%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Diaz JF, Valpuesta JM, Chacon P, Diakun G, Andreu JM. Changes in microtubule protofilament number induced by Taxol binding to an easily accessible site. Internal microtubule dynamics. J Biol Chem 1998;273:33803–10.</BibUnstructured>
            </Citation>
            <Citation ID="CR55_16">
              <CitationNumber>55</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Parness</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SB</Initials>
                  <FamilyName>Horwitz</FamilyName>
                </BibAuthorName>
                <Year>1981</Year>
                <ArticleTitle Language="En">Taxol binds to polymerized tubulin in vitro</ArticleTitle>
                <JournalTitle>J Cell Biol</JournalTitle>
                <VolumeID>91</VolumeID>
                <FirstPage>479</FirstPage>
                <LastPage>87</LastPage>
                <Occurrence Type="PID">
                  <Handle>6118377</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaL38Xit12g</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Parness J, Horwitz SB. Taxol binds to polymerized tubulin in vitro. J Cell Biol 1981;91:479–87.</BibUnstructured>
            </Citation>
            <Citation ID="CR56_16">
              <CitationNumber>56</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Rao</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SB</Initials>
                  <FamilyName>Horwitz</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>I</Initials>
                  <FamilyName>Ringel</FamilyName>
                </BibAuthorName>
                <Year>1992</Year>
                <ArticleTitle Language="En">Direct photoaffinity labeling of tubulin with taxol</ArticleTitle>
                <JournalTitle>J Natl Cancer Inst</JournalTitle>
                <VolumeID>84</VolumeID>
                <FirstPage>785</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>1349352</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK38Xks1antb8%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Rao S, Horwitz SB, Ringel I. Direct photoaffinity labeling of tubulin with taxol. J Natl Cancer Inst 1992;84:785–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR57_16">
              <CitationNumber>57</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Lowe</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Li</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KH</Initials>
                  <FamilyName>Downing</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Nogales</FamilyName>
                </BibAuthorName>
                <Year>2001</Year>
                <ArticleTitle Language="En">Refined structure of alpha beta-tubulin at 3.5 Å resolution</ArticleTitle>
                <JournalTitle>J Mol Biol</JournalTitle>
                <VolumeID>313</VolumeID>
                <FirstPage>1045</FirstPage>
                <LastPage>57</LastPage>
                <Occurrence Type="PID">
                  <Handle>11700061</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DC%2BD3Mnksl2muw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Lowe J, Li H, Downing KH, Nogales E. Refined structure of alpha beta-tubulin at 3.5 Å resolution. J Mol Biol 2001;313:1045–57.</BibUnstructured>
            </Citation>
            <Citation ID="CR58_16">
              <CitationNumber>58</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MA</Initials>
                  <FamilyName>Jordan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RJ</Initials>
                  <FamilyName>Toso</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Thrower</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Wilson</FamilyName>
                </BibAuthorName>
                <Year>1993</Year>
                <ArticleTitle Language="En">Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations</ArticleTitle>
                <JournalTitle>Proc Natl Acad Sci U S A</JournalTitle>
                <VolumeID>90</VolumeID>
                <FirstPage>9552</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>8105478</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK3sXms1aisrg%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Jordan MA, Toso RJ, Thrower D, Wilson L. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci U S A 1993;90:9552–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR59_16">
              <CitationNumber>59</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>WB</Initials>
                  <FamilyName>Derry</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Wilson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MA</Initials>
                  <FamilyName>Jordan</FamilyName>
                </BibAuthorName>
                <Year>1995</Year>
                <ArticleTitle Language="En">Substoichiometric binding of taxol suppresses microtubule dynamics</ArticleTitle>
                <JournalTitle>Biochemistry</JournalTitle>
                <VolumeID>34</VolumeID>
                <FirstPage>2203</FirstPage>
                <LastPage>11</LastPage>
                <Occurrence Type="PID">
                  <Handle>7857932</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2MXjs1CntrY%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Derry WB, Wilson L, Jordan MA. Substoichiometric binding of taxol suppresses microtubule dynamics. Biochemistry 1995;34:2203–11.</BibUnstructured>
            </Citation>
            <Citation ID="CR60_16">
              <CitationNumber>60</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JG</Initials>
                  <FamilyName>Chen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SB</Initials>
                  <FamilyName>Horwitz</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">Differential mitotic responses to microtubule-stabilizing and -destabilizing drugs</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>62</VolumeID>
                <FirstPage>1935</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>11929805</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XivVyltLg%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Chen JG, Horwitz SB. Differential mitotic responses to microtubule-stabilizing and -destabilizing drugs. Cancer Res 2002;62:1935–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR61_16">
              <CitationNumber>61</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Torres</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SB</Initials>
                  <FamilyName>Horwitz</FamilyName>
                </BibAuthorName>
                <Year>1998</Year>
                <ArticleTitle Language="En">Mechanisms of taxol-induced cell death are concentration dependent</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>58</VolumeID>
                <FirstPage>3620</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>9721870</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1cXlsFajt7o%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Torres K, Horwitz SB. Mechanisms of taxol-induced cell death are concentration dependent. Cancer Res 1998;58:3620–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR62_16">
              <CitationNumber>62</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Rao</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>NE</Initials>
                  <FamilyName>Krauss</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JM</Initials>
                  <FamilyName>Heerding</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CS</Initials>
                  <FamilyName>Swindell</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>I</Initials>
                  <FamilyName>Ringel</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GA</Initials>
                  <FamilyName>Orr</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SB</Initials>
                  <FamilyName>Horwitz</FamilyName>
                </BibAuthorName>
                <Year>1994</Year>
                <ArticleTitle Language="En">3′-(p-azidobenzamido)taxol photolabels the N-terminal 31 amino acids of beta-tubulin</ArticleTitle>
                <JournalTitle>J Biol Chem</JournalTitle>
                <VolumeID>269</VolumeID>
                <FirstPage>3132</FirstPage>
                <LastPage>4</LastPage>
                <Occurrence Type="PID">
                  <Handle>7906266</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2cXhvVKhtbY%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Rao S, Krauss NE, Heerding JM, Swindell CS, Ringel I, Orr GA, et al. 3′-(p-azidobenzamido)taxol photolabels the N-terminal 31 amino acids of beta-tubulin. J Biol Chem 1994;269:3132–4.</BibUnstructured>
            </Citation>
            <Citation ID="CR63_16">
              <CitationNumber>63</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Rao</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GA</Initials>
                  <FamilyName>Orr</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AG</Initials>
                  <FamilyName>Chaudhary</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DG</Initials>
                  <FamilyName>Kingston</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SB</Initials>
                  <FamilyName>Horwitz</FamilyName>
                </BibAuthorName>
                <Year>1995</Year>
                <ArticleTitle Language="En">Characterization of the taxol binding site on the microtubule. 2-(m-Azidobenzoyl)taxol photolabels a peptide (amino acids 217-231) of beta-tubulin</ArticleTitle>
                <JournalTitle>J Biol Chem</JournalTitle>
                <VolumeID>270</VolumeID>
                <FirstPage>20235</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>7657589</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2MXnvVOqs74%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Rao S, Orr GA, Chaudhary AG, Kingston DG, Horwitz SB. Characterization of the taxol binding site on the microtubule. 2-(m-Azidobenzoyl)taxol photolabels a peptide (amino acids 217-231) of beta-tubulin. J Biol Chem 1995;270:20235–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR64_16">
              <CitationNumber>64</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>GA</Initials>
                  <FamilyName>Orr</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Rao</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CS</Initials>
                  <FamilyName>Swindell</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DG</Initials>
                  <FamilyName>Kingston</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SB</Initials>
                  <FamilyName>Horwitz</FamilyName>
                </BibAuthorName>
                <Year>1998</Year>
                <ArticleTitle Language="En">Photoaffinity labeling approach to map the taxol-binding site on the microtubule</ArticleTitle>
                <JournalTitle>Methods Enzymol</JournalTitle>
                <VolumeID>298</VolumeID>
                <FirstPage>238</FirstPage>
                <LastPage>52</LastPage>
                <Occurrence Type="PID">
                  <Handle>9751886</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1MXltlKj</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Orr GA, Rao S, Swindell CS, Kingston DG, Horwitz SB. Photoaffinity labeling approach to map the taxol-binding site on the microtubule. Methods Enzymol 1998;298:238–52.</BibUnstructured>
            </Citation>
            <Citation ID="CR65_16">
              <CitationNumber>65</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Rao</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>He</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Chakravarty</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>I</Initials>
                  <FamilyName>Ojima</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GA</Initials>
                  <FamilyName>Orr</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SB</Initials>
                  <FamilyName>Horwitz</FamilyName>
                </BibAuthorName>
                <Year>1999</Year>
                <ArticleTitle Language="En">Characterization of the taxol binding site on the microtubule. Identification of Arg(282) in beta-tubulin as the site of photoincorporation of a 7-benzophenone analogue of taxol</ArticleTitle>
                <JournalTitle>J Biol Chem</JournalTitle>
                <VolumeID>274</VolumeID>
                <FirstPage>37990</FirstPage>
                <LastPage>4</LastPage>
                <Occurrence Type="PID">
                  <Handle>10608867</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXkt1Gltw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Rao S, He L, Chakravarty S, Ojima I, Orr GA, Horwitz SB. Characterization of the taxol binding site on the microtubule. Identification of Arg(282) in beta-tubulin as the site of photoincorporation of a 7-benzophenone analogue of taxol. J Biol Chem 1999;274:37990–4.</BibUnstructured>
            </Citation>
            <Citation ID="CR66_16">
              <CitationNumber>66</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Rao</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Aberg</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Nieves</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SB</Initials>
                  <FamilyName>Horwitz</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GA</Initials>
                  <FamilyName>Orr</FamilyName>
                </BibAuthorName>
                <Year>2001</Year>
                <ArticleTitle Language="En">Identification by mass spectrometry of a new alpha-tubulin isotype expressed in human breast and lung carcinoma cell lines</ArticleTitle>
                <JournalTitle>Biochemistry</JournalTitle>
                <VolumeID>40</VolumeID>
                <FirstPage>2096</FirstPage>
                <LastPage>103</LastPage>
                <Occurrence Type="PID">
                  <Handle>11329278</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXmtFykug%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Rao S, Aberg F, Nieves E, Horwitz SB, Orr GA. Identification by mass spectrometry of a new alpha-tubulin isotype expressed in human breast and lung carcinoma cell lines. Biochemistry 2001;40:2096–103.</BibUnstructured>
            </Citation>
            <Citation ID="CR67_16">
              <CitationNumber>67</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Nogales</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SG</Initials>
                  <FamilyName>Wolf</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KH</Initials>
                  <FamilyName>Downing</FamilyName>
                </BibAuthorName>
                <Year>1998</Year>
                <ArticleTitle Language="En">Structure of the alpha beta tubulin dimer by electron crystallography</ArticleTitle>
                <JournalTitle>Nature</JournalTitle>
                <VolumeID>391</VolumeID>
                <FirstPage>199</FirstPage>
                <LastPage>203</LastPage>
                <Occurrence Type="PID">
                  <Handle>9428769</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1cXmt1Kisw%3D%3D</Handle>
                </Occurrence>
                <BibComments>erratum in: Nature 393:191</BibComments>
              </BibArticle>
              <BibUnstructured>Nogales E, Wolf SG, Downing KH. Structure of the alpha beta tubulin dimer by electron crystallography. Nature 1998;391:199–203. erratum in: Nature 393:191.</BibUnstructured>
            </Citation>
            <Citation ID="CR68_16">
              <CitationNumber>68</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DM</Initials>
                  <FamilyName>Bollag</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PA</Initials>
                  <FamilyName>McQueney</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Zhu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>O</Initials>
                  <FamilyName>Hensens</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Koupal</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Liesch</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Goetz</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Lazarides</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CM</Initials>
                  <FamilyName>Woods</FamilyName>
                </BibAuthorName>
                <Year>1995</Year>
                <ArticleTitle Language="En">Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>55</VolumeID>
                <FirstPage>2325</FirstPage>
                <LastPage>33</LastPage>
                <Occurrence Type="PID">
                  <Handle>7757983</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2MXlvFeqsr0%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Bollag DM, McQueney PA, Zhu J, Hensens O, Koupal L, Liesch J, et al. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res 1995;55:2325–33.</BibUnstructured>
            </Citation>
            <Citation ID="CR69_16">
              <CitationNumber>69</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Haar</FamilyName>
                  <Particle>ter</Particle>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RJ</Initials>
                  <FamilyName>Kowalski</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Hamel</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CM</Initials>
                  <FamilyName>Lin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RE</Initials>
                  <FamilyName>Longley</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SP</Initials>
                  <FamilyName>Gunasekera</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>HS</Initials>
                  <FamilyName>Rosenkranz</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>BW</Initials>
                  <FamilyName>Day</FamilyName>
                </BibAuthorName>
                <Year>1996</Year>
                <ArticleTitle Language="En">Discodermolide, a cytotoxic marine agent that stabilizes microtubules more potently than taxol</ArticleTitle>
                <JournalTitle>Biochemistry</JournalTitle>
                <VolumeID>35</VolumeID>
                <FirstPage>243</FirstPage>
                <LastPage>50</LastPage>
                <Occurrence Type="PID">
                  <Handle>8555181</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>ter Haar E, Kowalski RJ, Hamel E, Lin CM, Longley RE, Gunasekera SP, et al. Discodermolide, a cytotoxic marine agent that stabilizes microtubules more potently than taxol. Biochemistry 1996;35:243–50.</BibUnstructured>
            </Citation>
            <Citation ID="CR70_16">
              <CitationNumber>70</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>He</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GA</Initials>
                  <FamilyName>Orr</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SB</Initials>
                  <FamilyName>Horwitz</FamilyName>
                </BibAuthorName>
                <Year>2001</Year>
                <ArticleTitle Language="En">Novel molecules that interact with microtubules and have functional activity similar to taxol</ArticleTitle>
                <JournalTitle>Drug Discov Today</JournalTitle>
                <VolumeID>6</VolumeID>
                <FirstPage>1153</FirstPage>
                <LastPage>64</LastPage>
                <Occurrence Type="PID">
                  <Handle>11700217</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXotFSntbo%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>He L, Orr GA, Horwitz SB. Novel molecules that interact with microtubules and have functional activity similar to taxol. Drug Discov Today 2001;6:1153–64.</BibUnstructured>
            </Citation>
            <Citation ID="CR71_16">
              <CitationNumber>71</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DT</Initials>
                  <FamilyName>Hung</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Chen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SL</Initials>
                  <FamilyName>Schreiber</FamilyName>
                </BibAuthorName>
                <Year>1996</Year>
                <ArticleTitle Language="En">(+)-Discodermolide binds to microtubules in stoichiometric ratio to tubulin dimers, blocks taxol binding and results in mitotic arrest</ArticleTitle>
                <JournalTitle>Chem Biol</JournalTitle>
                <VolumeID>3</VolumeID>
                <FirstPage>287</FirstPage>
                <LastPage>93</LastPage>
                <Occurrence Type="PID">
                  <Handle>8807856</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK28XjtVKhtr0%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Hung DT, Chen J, Schreiber SL. (+)-Discodermolide binds to microtubules in stoichiometric ratio to tubulin dimers, blocks taxol binding and results in mitotic arrest. Chem Biol 1996;3:287–93.</BibUnstructured>
            </Citation>
            <Citation ID="CR72_16">
              <CitationNumber>72</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>RJ</Initials>
                  <FamilyName>Kowalski</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Giannakakou</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SP</Initials>
                  <FamilyName>Gunasekera</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RE</Initials>
                  <FamilyName>Longley</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>BW</Initials>
                  <FamilyName>Day</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Hamel</FamilyName>
                </BibAuthorName>
                <Year>1997</Year>
                <ArticleTitle Language="En">The microtubule-stabilizing agent discodermolide competitively inhibits the binding of paclitaxel (Taxol) to tubulin polymers, enhances tubulin nucleation reactions more potently than paclitaxel, and inhibits the growth of paclitaxel-resistant cells</ArticleTitle>
                <JournalTitle>Mol Pharmacol</JournalTitle>
                <VolumeID>52</VolumeID>
                <FirstPage>613</FirstPage>
                <LastPage>22</LastPage>
                <Occurrence Type="PID">
                  <Handle>9380024</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2sXmvFaku7g%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Kowalski RJ, Giannakakou P, Gunasekera SP, Longley RE, Day BW, Hamel E. The microtubule-stabilizing agent discodermolide competitively inhibits the binding of paclitaxel (Taxol) to tubulin polymers, enhances tubulin nucleation reactions more potently than paclitaxel, and inhibits the growth of paclitaxel-resistant cells. Mol Pharmacol 1997;52:613–22.</BibUnstructured>
            </Citation>
            <Citation ID="CR73_16">
              <CitationNumber>73</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>BH</Initials>
                  <FamilyName>Long</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JM</Initials>
                  <FamilyName>Carboni</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AJ</Initials>
                  <FamilyName>Wasserman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LA</Initials>
                  <FamilyName>Cornell</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AM</Initials>
                  <FamilyName>Casazza</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PR</Initials>
                  <FamilyName>Jensen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Lindel</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>W</Initials>
                  <FamilyName>Fenical</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CR</Initials>
                  <FamilyName>Fairchild</FamilyName>
                </BibAuthorName>
                <Year>1998</Year>
                <ArticleTitle Language="En">Eleutherobin, a novel cytotoxic agent that induces tubulin polymerization, is similar to paclitaxel (taxol)</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>58</VolumeID>
                <FirstPage>1111</FirstPage>
                <LastPage>5</LastPage>
                <Occurrence Type="PID">
                  <Handle>9515790</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1cXhvV2ku7g%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Long BH, Carboni JM, Wasserman AJ, Cornell LA, Casazza AM, Jensen PR, et al. Eleutherobin, a novel cytotoxic agent that induces tubulin polymerization, is similar to paclitaxel (taxol). Cancer Res 1998;58:1111–5.</BibUnstructured>
            </Citation>
            <Citation ID="CR74_16">
              <CitationNumber>74</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Hamel</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DL</Initials>
                  <FamilyName>Sackett</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Vourloumis</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KC</Initials>
                  <FamilyName>Nicolaou</FamilyName>
                </BibAuthorName>
                <Year>1999</Year>
                <ArticleTitle Language="En">The coral-derived natural products eleutherobin and sarcodictyins A and B: effects on the assembly of purified tubulin with and without microtubule-associated proteins and binding at the polymer taxoid site</ArticleTitle>
                <JournalTitle>Biochemistry</JournalTitle>
                <VolumeID>38</VolumeID>
                <FirstPage>5490</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>10220336</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1MXitFGqtbk%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Hamel E, Sackett DL, Vourloumis D, Nicolaou KC. The coral-derived natural products eleutherobin and sarcodictyins A and B: effects on the assembly of purified tubulin with and without microtubule-associated proteins and binding at the polymer taxoid site. Biochemistry 1999;38:5490–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR75_16">
              <CitationNumber>75</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>SL</Initials>
                  <FamilyName>Mooberry</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Tien</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AH</Initials>
                  <FamilyName>Hernandez</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Plubrukarn</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>BS</Initials>
                  <FamilyName>Davison</FamilyName>
                </BibAuthorName>
                <Year>1999</Year>
                <ArticleTitle Language="En">Laulimalide and isolaulimalide, new paclitaxel-like microtubule-stabilizing agents</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>59</VolumeID>
                <FirstPage>653</FirstPage>
                <LastPage>60</LastPage>
                <Occurrence Type="PID">
                  <Handle>9973214</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1MXhtV2rtLY%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Mooberry SL, Tien G, Hernandez AH, Plubrukarn A, Davison BS. Laulimalide and isolaulimalide, new paclitaxel-like microtubule-stabilizing agents. Cancer Res 1999;59:653–60.</BibUnstructured>
            </Citation>
            <Citation ID="CR76_16">
              <CitationNumber>76</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DE</Initials>
                  <FamilyName>Pryor</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>O’Brate</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Bilcer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JF</Initials>
                  <FamilyName>Diaz</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Wang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Kabaki</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MK</Initials>
                  <FamilyName>Jung</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JM</Initials>
                  <FamilyName>Andreu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AK</Initials>
                  <FamilyName>Ghosh</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Giannakakou</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Hamel</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">The microtubule stabilizing agent laulimalide does not bind in the taxoid site, kills cells resistant to paclitaxel and epothilones, and may not require its epoxide moiety for activity</ArticleTitle>
                <JournalTitle>Biochemistry</JournalTitle>
                <VolumeID>41</VolumeID>
                <FirstPage>9109</FirstPage>
                <LastPage>15</LastPage>
                <Occurrence Type="PID">
                  <Handle>12119025</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XkslehsLk%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Pryor DE, O’Brate A, Bilcer G, Diaz JF, Wang Y, Kabaki M, et al. The microtubule stabilizing agent laulimalide does not bind in the taxoid site, kills cells resistant to paclitaxel and epothilones, and may not require its epoxide moiety for activity. Biochemistry 2002;41:9109–15.</BibUnstructured>
            </Citation>
            <Citation ID="CR77_16">
              <CitationNumber>77</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>O</Initials>
                  <FamilyName>Pineda</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Farras</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Maccari</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Manetti</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Botta</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Vilarrasa</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Computational comparison of microtubule-stabilising agents laulimalide and peloruside with taxol and colchicine</ArticleTitle>
                <JournalTitle>Bioorg Med Chem Lett</JournalTitle>
                <VolumeID>14</VolumeID>
                <FirstPage>4825</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>15341932</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXnt12rsLc%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Pineda O, Farras J, Maccari L, Manetti F, Botta M, Vilarrasa J. Computational comparison of microtubule-stabilising agents laulimalide and peloruside with taxol and colchicine. Bioorg Med Chem Lett 2004;14:4825–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR78_16">
              <CitationNumber>78</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AT</Initials>
                  <FamilyName>Fojo</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Whang-Peng</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MM</Initials>
                  <FamilyName>Gottesman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>I</Initials>
                  <FamilyName>Pastan</FamilyName>
                </BibAuthorName>
                <Year>1985</Year>
                <ArticleTitle Language="En">Amplification of DNA sequences in human multidrug-resistant KB carcinoma cells</ArticleTitle>
                <JournalTitle>Proc Natl Acad Sci U S A</JournalTitle>
                <VolumeID>82</VolumeID>
                <FirstPage>7661</FirstPage>
                <LastPage>5</LastPage>
                <Occurrence Type="PID">
                  <Handle>3865187</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaL28XivFOjtg%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Fojo AT, Whang-Peng J, Gottesman MM, Pastan I. Amplification of DNA sequences in human multidrug-resistant KB carcinoma cells. Proc Natl Acad Sci U S A 1985;82:7661–5.</BibUnstructured>
            </Citation>
            <Citation ID="CR79_16">
              <CitationNumber>79</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Hari</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Wang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Veeraraghavan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Cabral</FamilyName>
                </BibAuthorName>
                <Year>2003</Year>
                <ArticleTitle Language="En">Mutations in alpha- and beta-tubulin that stabilize microtubules and confer resistance to colcemid and vinblastine</ArticleTitle>
                <JournalTitle>Mol Cancer Ther</JournalTitle>
                <VolumeID>2</VolumeID>
                <FirstPage>597</FirstPage>
                <LastPage>605</LastPage>
                <Occurrence Type="PID">
                  <Handle>12883031</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXmsFGksbo%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Hari M, Wang Y, Veeraraghavan S, Cabral F. Mutations in alpha- and beta-tubulin that stabilize microtubules and confer resistance to colcemid and vinblastine. Mol Cancer Ther 2003;2:597–605.</BibUnstructured>
            </Citation>
            <Citation ID="CR80_16">
              <CitationNumber>80</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Giannakakou</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DL</Initials>
                  <FamilyName>Sackett</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>YK</Initials>
                  <FamilyName>Kang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Z</Initials>
                  <FamilyName>Zhan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JT</Initials>
                  <FamilyName>Buters</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Fojo</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MS</Initials>
                  <FamilyName>Poruchynsky</FamilyName>
                </BibAuthorName>
                <Year>1997</Year>
                <ArticleTitle Language="En">Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization</ArticleTitle>
                <JournalTitle>J Biol Chem</JournalTitle>
                <VolumeID>272</VolumeID>
                <FirstPage>17118</FirstPage>
                <LastPage>25</LastPage>
                <Occurrence Type="PID">
                  <Handle>9202030</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2sXksVemt70%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Giannakakou P, Sackett DL, Kang YK, Zhan Z, Buters JT, Fojo T, et al. Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 1997;272:17118–25.</BibUnstructured>
            </Citation>
            <Citation ID="CR81_16">
              <CitationNumber>81</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Giannakakou</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DL</Initials>
                  <FamilyName>Sackett</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Ward</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KR</Initials>
                  <FamilyName>Webster</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MV</Initials>
                  <FamilyName>Blagosklonny</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Fojo</FamilyName>
                </BibAuthorName>
                <Year>2000</Year>
                <ArticleTitle Language="En">p53 is associated with cellular microtubules and is transported to the nucleus by dynein</ArticleTitle>
                <JournalTitle>Nat Cell Biol</JournalTitle>
                <VolumeID>2</VolumeID>
                <FirstPage>709</FirstPage>
                <LastPage>17</LastPage>
                <Occurrence Type="PID">
                  <Handle>11025661</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXnsVyntL0%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Giannakakou P, Sackett DL, Ward Y, Webster KR, Blagosklonny MV, Fojo T. p53 is associated with cellular microtubules and is transported to the nucleus by dynein. Nat Cell Biol 2000;2:709–17.</BibUnstructured>
            </Citation>
            <Citation ID="CR82_16">
              <CitationNumber>82</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Hari</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Loganzo</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Annable</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>X</Initials>
                  <FamilyName>Tan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Musto</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DB</Initials>
                  <FamilyName>Morilla</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JH</Initials>
                  <FamilyName>Nettles</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JP</Initials>
                  <FamilyName>Snyder</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LM</Initials>
                  <FamilyName>Greenberger</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of beta-tubulin (Asp26Glu) and less stable microtubules</ArticleTitle>
                <JournalTitle>Mol Cancer Ther</JournalTitle>
                <VolumeID>5</VolumeID>
                <FirstPage>270</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>16505100</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XhvVels7o%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Hari M, Loganzo F, Annable T, Tan X, Musto S, Morilla DB, et al. Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of beta-tubulin (Asp26Glu) and less stable microtubules. Mol Cancer Ther 2006;5:270–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR83_16">
              <CitationNumber>83</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>FR</Initials>
                  <FamilyName>Cabral</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RC</Initials>
                  <FamilyName>Brady</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MJ</Initials>
                  <FamilyName>Schibler</FamilyName>
                </BibAuthorName>
                <Year>1986</Year>
                <ArticleTitle Language="En">A mechanism of cellular resistance to drugs that interfere with microtubule assembly</ArticleTitle>
                <JournalTitle>Ann N Y Acad Sci</JournalTitle>
                <VolumeID>466</VolumeID>
                <FirstPage>745</FirstPage>
                <LastPage>56</LastPage>
                <Occurrence Type="PID">
                  <Handle>2873781</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaL28Xls1ChtLk%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Cabral FR, Brady RC, Schibler MJ. A mechanism of cellular resistance to drugs that interfere with microtubule assembly. Ann N Y Acad Sci 1986;466:745–56.</BibUnstructured>
            </Citation>
            <Citation ID="CR84_16">
              <CitationNumber>84</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Cabral</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SB</Initials>
                  <FamilyName>Barlow</FamilyName>
                </BibAuthorName>
                <Year>1989</Year>
                <ArticleTitle Language="En">Mechanisms by which mammalian cells acquire resistance to drugs that affect microtubule assembly</ArticleTitle>
                <JournalTitle>FASEB J</JournalTitle>
                <VolumeID>3</VolumeID>
                <FirstPage>1593</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>2646163</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaL1MXhs1Ggsbg%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Cabral F, Barlow SB. Mechanisms by which mammalian cells acquire resistance to drugs that affect microtubule assembly. FASEB J 1989;3:1593–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR85_16">
              <CitationNumber>85</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AM</Initials>
                  <FamilyName>Minotti</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SB</Initials>
                  <FamilyName>Barlow</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Cabral</FamilyName>
                </BibAuthorName>
                <Year>1991</Year>
                <ArticleTitle Language="En">Resistance to antimitotic drugs in Chinese hamster ovary cells correlates with changes in the level of polymerized tubulin</ArticleTitle>
                <JournalTitle>J Biol Chem</JournalTitle>
                <VolumeID>266</VolumeID>
                <FirstPage>3987</FirstPage>
                <LastPage>94</LastPage>
                <Occurrence Type="PID">
                  <Handle>1671676</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK3MXhtlGks74%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Minotti AM, Barlow SB, Cabral F. Resistance to antimitotic drugs in Chinese hamster ovary cells correlates with changes in the level of polymerized tubulin. J Biol Chem 1991;266:3987–94.</BibUnstructured>
            </Citation>
            <Citation ID="CR86_16">
              <CitationNumber>86</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Wilson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MA</Initials>
                  <FamilyName>Jordan</FamilyName>
                </BibAuthorName>
                <Year>1995</Year>
                <ArticleTitle Language="En">Microtubule dynamics: taking aim at a moving target</ArticleTitle>
                <JournalTitle>Chem Biol</JournalTitle>
                <VolumeID>2</VolumeID>
                <FirstPage>569</FirstPage>
                <LastPage>73</LastPage>
                <Occurrence Type="PID">
                  <Handle>9383460</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2MXos1Wjtbw%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Wilson L, Jordan MA. Microtubule dynamics: taking aim at a moving target. Chem Biol 1995;2:569–73.</BibUnstructured>
            </Citation>
            <Citation ID="CR87_16">
              <CitationNumber>87</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MA</Initials>
                  <FamilyName>Jordan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Wilson</FamilyName>
                </BibAuthorName>
                <Year>1998</Year>
                <ArticleTitle Language="En">Microtubules and actin filaments: dynamic targets for cancer chemotherapy</ArticleTitle>
                <JournalTitle>Curr Opin Cell Biol</JournalTitle>
                <VolumeID>10</VolumeID>
                <FirstPage>123</FirstPage>
                <LastPage>30</LastPage>
                <Occurrence Type="PID">
                  <Handle>9484604</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1cXhtFSjsrg%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Jordan MA, Wilson L. Microtubules and actin filaments: dynamic targets for cancer chemotherapy. Curr Opin Cell Biol 1998;10:123–30.</BibUnstructured>
            </Citation>
            <Citation ID="CR88_16">
              <CitationNumber>88</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Goncalves</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Braguer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Kamath</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Martello</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Briand</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Horwitz</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Wilson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MA</Initials>
                  <FamilyName>Jordan</FamilyName>
                </BibAuthorName>
                <Year>2001</Year>
                <ArticleTitle Language="En">Resistance to taxol in lung cancer cells associated with increased microtubule dynamics</ArticleTitle>
                <JournalTitle>Proc Natl Acad Sci U S A</JournalTitle>
                <VolumeID>98</VolumeID>
                <FirstPage>11737</FirstPage>
                <LastPage>42</LastPage>
                <Occurrence Type="PID">
                  <Handle>11562465</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXnt12jsbc%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Goncalves A, Braguer D, Kamath K, Martello L, Briand C, Horwitz S, et al. Resistance to taxol in lung cancer cells associated with increased microtubule dynamics. Proc Natl Acad Sci U S A 2001;98:11737–42.</BibUnstructured>
            </Citation>
            <Citation ID="CR89_16">
              <CitationNumber>89</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AT</Initials>
                  <FamilyName>Fojo</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Menefee</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">Microtubule targeting agents: basic mechanisms of multidrug resistance (MDR)</ArticleTitle>
                <JournalTitle>Semin Oncol</JournalTitle>
                <VolumeID>32</VolumeID>
                <FirstPage>S3</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>16360716</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XntlWlsw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Fojo AT, Menefee M. Microtubule targeting agents: basic mechanisms of multidrug resistance (MDR). Semin Oncol 2005;32:S3–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR90_16">
              <CitationNumber>90</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Jemal</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Siegel</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Ward</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2009</Year>
                <ArticleTitle Language="En">Cancer Statistics, CA Cancer</ArticleTitle>
                <JournalTitle>J Clin</JournalTitle>
                <VolumeID>59</VolumeID>
                <FirstPage>225</FirstPage>
                <LastPage>49</LastPage>
              </BibArticle>
              <BibUnstructured>Jemal A, Siegel R, Ward E, et al. Cancer Statistics, CA Cancer. J Clin 2009;59:225–49.</BibUnstructured>
            </Citation>
            <Citation ID="CR91_16">
              <CitationNumber>91</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>IF</Initials>
                  <FamilyName>Tannock</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Wit</FamilyName>
                  <Particle>de</Particle>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>W</Initials>
                  <FamilyName>Berry</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer</ArticleTitle>
                <JournalTitle>N Engl J Med</JournalTitle>
                <VolumeID>351</VolumeID>
                <FirstPage>1502</FirstPage>
                <LastPage>12</LastPage>
                <Occurrence Type="PID">
                  <Handle>15470213</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXot1Kmu7s%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Tannock IF, de Wit R, Berry W, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502–12.</BibUnstructured>
            </Citation>
            <Citation ID="CR92_16">
              <CitationNumber>92</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DP</Initials>
                  <FamilyName>Petrylak</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CM</Initials>
                  <FamilyName>Tangen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Hussain</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer</ArticleTitle>
                <JournalTitle>N Engl J Med</JournalTitle>
                <VolumeID>351</VolumeID>
                <FirstPage>1513</FirstPage>
                <LastPage>20</LastPage>
                <Occurrence Type="PID">
                  <Handle>15470214</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXot1Kmu7c%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Petrylak DP, Tangen CM, Hussain M, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513–20.</BibUnstructured>
            </Citation>
            <Citation ID="CR93_16">
              <CitationNumber>93</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Dawson</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">Epothilones in prostate cancer: review of clinical experience</ArticleTitle>
                <JournalTitle>Ann Oncol</JournalTitle>
                <VolumeID>18</VolumeID>
                <IssueID>Suppl 5</IssueID>
                <FirstPage>v22</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>17656558</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Dawson N. Epothilones in prostate cancer: review of clinical experience. Ann Oncol 2007;18 Suppl 5:v22–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR94_16">
              <CitationNumber>94</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JJ</Initials>
                  <FamilyName>Lee</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WK</Initials>
                  <FamilyName>Kelly</FamilyName>
                </BibAuthorName>
                <Year>2009</Year>
                <ArticleTitle Language="En">Epothilones: tubulin polymerization as a novel target for prostate cancer therapy</ArticleTitle>
                <JournalTitle>Nat Clin Pract Oncol</JournalTitle>
                <VolumeID>6</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>85</FirstPage>
                <LastPage>92</LastPage>
                <Occurrence Type="PID">
                  <Handle>19048010</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1MXhtFOmtbs%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Lee JJ, Kelly WK. Epothilones: tubulin polymerization as a novel target for prostate cancer therapy. Nat Clin Pract Oncol 2009;6(2):85–92.</BibUnstructured>
            </Citation>
            <Citation ID="CR95_16">
              <CitationNumber>95</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>EK</Initials>
                  <FamilyName>Beardsley</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KN</Initials>
                  <FamilyName>Chi</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">Systemic therapy after first-line docetaxel in metastatic castration-resistant prostate cancer</ArticleTitle>
                <JournalTitle>Curr Opin Support Palliat Care</JournalTitle>
                <VolumeID>2</VolumeID>
                <FirstPage>161</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>18685415</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Beardsley EK, Chi KN. Systemic therapy after first-line docetaxel in metastatic castration-resistant prostate cancer. Curr Opin Support Palliat Care 2008;2:161–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR96_16">
              <CitationNumber>96</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Rivera</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Lee</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Davies</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors</ArticleTitle>
                <JournalTitle>Oncologist</JournalTitle>
                <VolumeID>13</VolumeID>
                <FirstPage>1207</FirstPage>
                <LastPage>23</LastPage>
                <Occurrence Type="PID">
                  <Handle>19088324</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1MXhvV2nurw%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Rivera E, Lee J, Davies A. Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors. Oncologist 2008;13:1207–23.</BibUnstructured>
            </Citation>
            <Citation ID="CR97_16">
              <CitationNumber>97</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Sepp-Lorenzino</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Balog</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DS</Initials>
                  <FamilyName>Su</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1999</Year>
                <ArticleTitle Language="En">The microtubule-stabilizing agents epothilones A and B and their desoxy-derivatives induce mitotic arrest and apoptosis in human prostate cancer cells</ArticleTitle>
                <JournalTitle>Prostate Cancer Prostatic Dis</JournalTitle>
                <VolumeID>2</VolumeID>
                <FirstPage>41</FirstPage>
                <LastPage>52</LastPage>
                <Occurrence Type="PID">
                  <Handle>12496865</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1MXhsVGju7o%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Sepp-Lorenzino L, Balog A, Su DS, et al. The microtubule-stabilizing agents epothilones A and B and their desoxy-derivatives induce mitotic arrest and apoptosis in human prostate cancer cells. Prostate Cancer Prostatic Dis 1999;2:41–52.</BibUnstructured>
            </Citation>
            <Citation ID="CR98_16">
              <CitationNumber>98</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>O’Reilly</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PM</Initials>
                  <FamilyName>McSheehy</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Wenger</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2005</Year>
                <ArticleTitle Language="En">Patupilone (epothilone B, EPO906) inhibits growth and metastasis of experimental prostate tumors in vivo</ArticleTitle>
                <JournalTitle>Prostate</JournalTitle>
                <VolumeID>65</VolumeID>
                <FirstPage>231</FirstPage>
                <LastPage>40</LastPage>
                <Occurrence Type="PID">
                  <Handle>15948135</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>O’Reilly T, McSheehy PM, Wenger F, et al. Patupilone (epothilone B, EPO906) inhibits growth and metastasis of experimental prostate tumors in vivo. Prostate 2005;65:231–40.</BibUnstructured>
            </Citation>
            <Citation ID="CR99_16">
              <CitationNumber>99</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>KH</Initials>
                  <FamilyName>Altmann</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">Recent developments in the chemical biology of epothilones</ArticleTitle>
                <JournalTitle>Curr Pharm Des</JournalTitle>
                <VolumeID>11</VolumeID>
                <FirstPage>1595</FirstPage>
                <LastPage>613</LastPage>
                <Occurrence Type="PID">
                  <Handle>15892665</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXktlajtbY%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Altmann KH. Recent developments in the chemical biology of epothilones. Curr Pharm Des 2005;11:1595–613.</BibUnstructured>
            </Citation>
            <Citation ID="CR100_16">
              <CitationNumber>100</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>RJ</Initials>
                  <FamilyName>Kowalski</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Giannakakou</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Hamel</FamilyName>
                </BibAuthorName>
                <Year>1997</Year>
                <ArticleTitle Language="En">Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol<Superscript>®</Superscript>)</ArticleTitle>
                <JournalTitle>J Biol Chem</JournalTitle>
                <VolumeID>272</VolumeID>
                <FirstPage>2534</FirstPage>
                <LastPage>41</LastPage>
                <Occurrence Type="PID">
                  <Handle>8999970</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2sXotFCitw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Kowalski RJ, Giannakakou P, Hamel E. Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol<Superscript>®</Superscript>). J Biol Chem 1997;272:2534–41.</BibUnstructured>
            </Citation>
            <Citation ID="CR101_16">
              <CitationNumber>101</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Wartmann</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KH</Initials>
                  <FamilyName>Altmann</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">The biology and medicinal chemistry of epothilones</ArticleTitle>
                <JournalTitle>Curr Med Chem Anticancer Agents</JournalTitle>
                <VolumeID>2</VolumeID>
                <FirstPage>123</FirstPage>
                <LastPage>48</LastPage>
                <Occurrence Type="PID">
                  <Handle>12678754</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XislGmu78%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Wartmann M, Altmann KH. The biology and medicinal chemistry of epothilones. Curr Med Chem Anticancer Agents 2002;2:123–48.</BibUnstructured>
            </Citation>
            <Citation ID="CR102_16">
              <CitationNumber>102</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>PM</Initials>
                  <FamilyName>Calvert</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>V</Initials>
                  <FamilyName>O’Neill</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Twelves</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2001</Year>
                <ArticleTitle Language="En">A phase I clinical and pharmacokinetic study of EPO906 (Epothilone B), given every three weeks, in patients with advanced solid tumors</ArticleTitle>
                <JournalTitle>Proc Am Soc Clin Oncol</JournalTitle>
                <VolumeID>20</VolumeID>
                <FirstPage>A429</FirstPage>
              </BibArticle>
              <BibUnstructured>Calvert PM, O’Neill V, Twelves C, et al. A phase I clinical and pharmacokinetic study of EPO906 (Epothilone B), given every three weeks, in patients with advanced solid tumors. Proc Am Soc Clin Oncol 2001;20:A429.</BibUnstructured>
            </Citation>
            <Citation ID="CR103_16">
              <CitationNumber>103</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>EH</Initials>
                  <FamilyName>Rubin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Rothermel</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Fisseha</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2005</Year>
                <ArticleTitle Language="En">Phase I dose-finding study of weekly single-agent patupilone in patients with advanced solid tumors</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>23</VolumeID>
                <FirstPage>9120</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>16301595</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28Xnt1ygtQ%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Rubin EH, Rothermel J, Fisseha T, et al. Phase I dose-finding study of weekly single-agent patupilone in patients with advanced solid tumors. J Clin Oncol 2005;23:9120–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR104_16">
              <CitationNumber>104</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>SM</Initials>
                  <FamilyName>Gadgeel</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Wozniak</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RR</Initials>
                  <FamilyName>Boinpally</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2005</Year>
                <ArticleTitle Language="En">Phase I clinical trial of BMS-247550, a derivative of epothilone B, using accelerated titration 2B design</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>11</VolumeID>
                <FirstPage>6233</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>16144926</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXpslansL4%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Gadgeel SM, Wozniak A, Boinpally RR, et al. Phase I clinical trial of BMS-247550, a derivative of epothilone B, using accelerated titration 2B design. Clin Cancer Res 2005;11:6233–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR105_16">
              <CitationNumber>105</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Aghajanian</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>HA</Initials>
                  <FamilyName>Burris</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Jones</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2007</Year>
                <ArticleTitle Language="En">Phase I study of the novel epothilone analog Ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>25</VolumeID>
                <FirstPage>1082</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>17261851</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXksVyrs70%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Aghajanian C, Burris HA, Jones S, et al. Phase I study of the novel epothilone analog Ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas. J Clin Oncol 2007;25:1082–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR106_16">
              <CitationNumber>106</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Hussain</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CM</Initials>
                  <FamilyName>Tangen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PN</Initials>
                  <FamilyName>Lara</FamilyName>
                  <Suffix>Jr</Suffix>
                </BibAuthorName>
                <Etal/>
                <Year>2005</Year>
                <ArticleTitle Language="En">Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naïve patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>23</VolumeID>
                <FirstPage>8724</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>16314632</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Hussain M, Tangen CM, Lara Jr PN, et al. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naïve patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111. J Clin Oncol 2005;23:8724–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR107_16">
              <CitationNumber>107</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MD</Initials>
                  <FamilyName>Galsky</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EJ</Initials>
                  <FamilyName>Small</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WK</Initials>
                  <FamilyName>Oh</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2005</Year>
                <ArticleTitle Language="En">Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>23</VolumeID>
                <FirstPage>1439</FirstPage>
                <LastPage>46</LastPage>
                <Occurrence Type="PID">
                  <Handle>15735119</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXis1Gnu7Y%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Galsky MD, Small EJ, Oh WK, et al. Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. J Clin Oncol 2005;23:1439–46.</BibUnstructured>
            </Citation>
            <Citation ID="CR108_16">
              <CitationNumber>108</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JE</Initials>
                  <FamilyName>Rosenberg</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>VK</Initials>
                  <FamilyName>Weinberg</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WK</Initials>
                  <FamilyName>Kelly</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2007</Year>
                <ArticleTitle Language="En">Activity of second-line chemotherapy in docetaxel-refractory hormone refractory prostate cancer patients. Randomized phase 2 study of ixabepilone or mitoxantrone and prednisone</ArticleTitle>
                <JournalTitle>Cancer</JournalTitle>
                <VolumeID>110</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>556</FirstPage>
                <LastPage>63</LastPage>
                <Occurrence Type="PID">
                  <Handle>17577218</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXpt1yqu7o%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Rosenberg JE, Weinberg VK, Kelly WK, et al. Activity of second-line chemotherapy in docetaxel-refractory hormone refractory prostate cancer patients. Randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer 2007;110(3):556–63.</BibUnstructured>
            </Citation>
            <Citation ID="CR109_16">
              <CitationNumber>109</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Wilding</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Chen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RP</Initials>
                  <FamilyName>DiPaola</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2008</Year>
                <ArticleTitle Language="En">E3803: updated results on phase II study of a weekly schedule of BMS-247550 for patients with castrate refractory prostate cancer (CRPC)</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>26</VolumeID>
                <IssueID>Suppl</IssueID>
                <FirstPage>A5070</FirstPage>
              </BibArticle>
              <BibUnstructured>Wilding G, Chen Y, DiPaola RP, et al. E3803: updated results on phase II study of a weekly schedule of BMS-247550 for patients with castrate refractory prostate cancer (CRPC). J Clin Oncol 2008;26(Suppl):A5070.</BibUnstructured>
            </Citation>
            <Citation ID="CR110_16">
              <CitationNumber>110</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>KN</Initials>
                  <FamilyName>Chi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EK</Initials>
                  <FamilyName>Beardsley</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PM</Initials>
                  <FamilyName>Venner</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2008</Year>
                <ArticleTitle Language="En">A phase II study of patupilone in patients with metastatic hormone refractory prostate cancer (HRPC) who have progressed after docetaxel</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>26</VolumeID>
                <IssueID>15S</IssueID>
                <FirstPage>516</FirstPage>
              </BibArticle>
              <BibUnstructured>Chi KN, Beardsley EK, Venner PM, et al. A phase II study of patupilone in patients with metastatic hormone refractory prostate cancer (HRPC) who have progressed after docetaxel. J Clin Oncol 2008;26(15S) May 20 Suppl:516.</BibUnstructured>
            </Citation>
            <Citation ID="CR111_16">
              <CitationNumber>111</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Hussain</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RS</Initials>
                  <FamilyName>DiPaola</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AD</Initials>
                  <FamilyName>Baron</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2009</Year>
                <ArticleTitle Language="En">Phase II trial of weekly patupilone in patients with castration-resistant prostate cancer</ArticleTitle>
                <JournalTitle>Ann Oncol</JournalTitle>
                <VolumeID>20</VolumeID>
                <FirstPage>492</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>19087985</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DC%2BD1M7mvVamtg%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Hussain A, DiPaola RS, Baron AD, et al. Phase II trial of weekly patupilone in patients with castration-resistant prostate cancer. Ann Oncol 2009;20:492–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR112_16">
              <CitationNumber>112</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>O</Initials>
                  <FamilyName>Smaletz</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Galsky</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>HI</Initials>
                  <FamilyName>Scher</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2003</Year>
                <ArticleTitle Language="En">Pilot study of epothilone B analog (BMS-247550) and estramustine phosphate in patients with progressive metastatic prostate cancer following castration</ArticleTitle>
                <JournalTitle>Ann Oncol</JournalTitle>
                <VolumeID>14</VolumeID>
                <FirstPage>1518</FirstPage>
                <LastPage>24</LastPage>
                <Occurrence Type="PID">
                  <Handle>14504052</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DC%2BD3svktlKjuw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Smaletz O, Galsky M, Scher HI, et al. Pilot study of epothilone B analog (BMS-247550) and estramustine phosphate in patients with progressive metastatic prostate cancer following castration. Ann Oncol 2003;14:1518–24.</BibUnstructured>
            </Citation>
            <Citation ID="CR113_16">
              <CitationNumber>113</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>TM</Initials>
                  <FamilyName>Beer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CS</Initials>
                  <FamilyName>Higano</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Saleh</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2007</Year>
                <ArticleTitle Language="En">Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel</ArticleTitle>
                <JournalTitle>Invest New Drugs</JournalTitle>
                <VolumeID>25</VolumeID>
                <FirstPage>565</FirstPage>
                <LastPage>70</LastPage>
                <Occurrence Type="PID">
                  <Handle>17618407</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXhtFSlsb%2FP</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Beer TM, Higano CS, Saleh M, et al. Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel. Invest New Drugs 2007;25:565–70.</BibUnstructured>
            </Citation>
            <Citation ID="CR114_16">
              <CitationNumber>114</CitationNumber>
              <BibBook>
                <InstitutionalAuthorName>Sanofi-aventis</InstitutionalAuthorName>
                <Year>2000</Year>
                <BookTitle>XRP6258 investigator’s brochure</BookTitle>
                <PublisherName>Sanofi-aventis</PublisherName>
                <PublisherLocation>Antony (France)</PublisherLocation>
              </BibBook>
              <BibUnstructured>Sanofi-aventis. XRP6258 investigator’s brochure. Antony (France): Sanofi-aventis; 2000.</BibUnstructured>
            </Citation>
            <Citation ID="CR115_16">
              <CitationNumber>115</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AC</Initials>
                  <FamilyName>Mita</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LJ</Initials>
                  <FamilyName>Denis</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EK</Initials>
                  <FamilyName>Rowinsky</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2009</Year>
                <ArticleTitle Language="En">Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane administered as a 10 hour infusion every 3 weeks in patients with advanced solid tumors</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>15</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>723</FirstPage>
                <LastPage>30</LastPage>
                <Occurrence Type="PID">
                  <Handle>19147780</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1MXlvFCjsQ%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Mita AC, Denis LJ, Rowinsky EK, et al. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane administered as a 10 hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res 2009;15(2):723–30.</BibUnstructured>
            </Citation>
            <Citation ID="CR116_16">
              <CitationNumber>116</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>X</Initials>
                  <FamilyName>Pivot</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Koralewski</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JL</Initials>
                  <FamilyName>Hidalgo</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2008</Year>
                <ArticleTitle Language="En">A multicenter phase II study of XRP6528 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients</ArticleTitle>
                <JournalTitle>Ann Oncol</JournalTitle>
                <VolumeID>19</VolumeID>
                <IssueID>9</IssueID>
                <FirstPage>1547</FirstPage>
                <LastPage>52</LastPage>
                <Occurrence Type="PID">
                  <Handle>18436520</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DC%2BD1crivFWmsg%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Pivot X, Koralewski P, Hidalgo JL, et al. A multicenter phase II study of XRP6528 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Ann Oncol 2008;19(9):1547–52.</BibUnstructured>
            </Citation>
            <Citation ID="CR117_16">
              <CitationNumber>117</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JS</Initials>
                  <FamilyName>Bono</FamilyName>
                  <Particle>De</Particle>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Oudard</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Ozguroglu</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2010</Year>
                <ArticleTitle Language="En">Cabazitaxel or mitosantrone with presdnisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: Final results of a multinational phase III trial (TROPIC). ASCO Annual Meeting Proceedings</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>28</VolumeID>
                <FirstPage>4508</FirstPage>
              </BibArticle>
              <BibUnstructured>De Bono JS, Oudard S, Ozguroglu M, et al. Cabazitaxel or mitosantrone with presdnisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: Final results of a multinational phase III trial (TROPIC). ASCO Annual Meeting Proceedings. J Clin Oncol 2010;28:4508.</BibUnstructured>
            </Citation>
          </Bibliography>
        </ChapterBackmatter>
      </Chapter>
    </Part>
  </Book>
</Publisher>
